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Making Access to Pharmaceuticals a Reality:
Legal Options Under TRIPS and the Case of
Brazil
Zita Lazzarinit
The HIV/AIDS epidemic has made the problem of access to
pharmaceuticals in developing countries a subject of intense public
debate. This Essay contends that tensions between intellectual property
rights and human rights are largely resolvable through the full utilization
of exceptions under new international trade and intellectual property
rules. Rather than undermining these regimes, the approach laid out in
this Essay was anticipated by the international forum that established the
World Trade Organization and issued the Trade-Related Aspects of
Intellectual Property Agreement (TRIPS). Brazil's experience illustrates
possible strategies, relevant to developing countries, which can be used to
strike a balance between respect for public health and human rights and
protection of intellectual property rights.
I. INTRODUCrION
Extreme disparities in access to pharmaceuticals for life-threatening
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diseases are not new. Although much of the world has always lacked
access to new and expensive drugs, only now are we seriously discussing
these disparities. Spurred by the growing HIV/AIDS epidemic as well as
the globalization of international trade, these questions have landed
squarely in the public arena.
This Essay will investigate the problem of access to pharmaceuticals in
the context of intellectual property rules and human rights. As long as
concepts like sharing equitably in the benefits of science and technology,
safeguarding the rights of indigenous peoples, and protecting "authors'
rights" remain unrealized and unreconciled, access to pharmaceuticals will
continue to be an issue of charity rather than of rights, and good health will
remain beyond the grasp of most of the world. In this Essay, I will not
venture an exhaustive exploration of the empirical evidence related to drug
pricing or a detailed examination of the legal mechanisms available to
facilitate access in all countries. Instead, I will lay the groundwork for
possible ways to resolve the tension between intellectual property rights
and human rights in the effort to guarantee access to pharmaceuticals.
This Essay suggests that many middle-income countries could provide
wider access to pharmaceuticals by fully utilizing the exceptions permitted
under new international trade and intellectual property rules. For the
poorest nations, however, these rules as written do not offer easy solutions.
Moreover, rich nations have been slow to recognize-and poor nations
have been slow to use -the potential exceptions within the existing regime.
This Essay will draw on the recent experience of Brazil to illustrate possible
strategies and several notable trends.
Part I briefly describes global disparities in health and access to
pharmaceuticals. Part II sheds light upon some of the barriers to wider
access to pharmaceuticals related to HIV/AIDS and reviews the basic
structure of international intellectual property law. Part III characterizes
access to pharmaceuticals as a human right. Part IV considers ways to
reconcile the existing tension between intellectual property rules and
human rights. Part V presents Brazil as a case study, considering the
relevance of its experience for other developing countries. Finally, Part VI
concludes with proposed directions for further inquiry.
II. DISPARITIES IN HEALTH AND DISPARITIES IN ACCESS
If you live in a poor country, you are much more likely to suffer early
sickness, disability and death than if you live in a rich country. The World
Health Organization (WHO) reports that such glaring disparities in health
conditions, incidence and prevalence of disease, and life expectancy
persist.' Unsurprisingly, access to pharmaceuticals also varies
tremendously around the world. Despite years of WHO's essential drug
1. WORLD HEALTH ORGANIZATION, THE WORLD HEALTH REPORT 1999: MAKING A
DIFFERENCE 13-20 (1999) (describing the significant disparities in health status that exist
between rich and poor countries).
[Vol. 6
2
Yale Human Rights and Development Law Journal, Vol. 6 [2003], Iss. 1, Art. 4
https://digitalcommons.law.yale.edu/yhrdlj/vol6/iss1/4
2003] Access to Pharmaceuticals
programs and the adoption of essential drug lists by many countries, 2
availability of drugs remains highly uneven.3 The World Health Assembly
has noted that "one third of the world's population has no guaranteed
access to essential drugs." 4 In many developing countries, individuals and
their families are expected to purchase drugs and medicines to treat their
illnesses.5 Weak government regulation and improper prescriptions from
doctors may result in unsafe and ineffective drug use.6 The danger of
misuse is especially strong with antibiotics. 7 For many serious diseases,
treatments are either unavailable or unaffordable.8 In rural areas the
situation is particularly difficult, as the only supplier of drugs is typically
either a local hospital or health clinic which often lacks even the most basic
drugs to treat common illnesses such as respiratory infections and diarrhea
and very rarely has access to new drugs used to treat tuberculosis or
HIV/AIDS.9 Only a wealthy few in most countries can even think of
obtaining HIV/AIDS drugs independently. 10
Disparities in access to pharmaceuticals exact an unmistakable impact
on health. Three million people died of AIDS in 2001. In 2000, 1.7 million
died of tuberculosis and more than one million from malaria. 1 With the
use of combination therapy in the United States and in other developed
countries since 1996, AIDS cases and deaths have dropped substantially for
2. WORLD HEALTH ORGANIZATION, ESSENTIAL DRUG AND MEDICINES POLICY: HIGHLIGHTS-
WHO MEDICINES STRATEGY: 2000-2003, at http://www.who.int/medicines/strategv/
whozipl6e/ch03.htm (last visited Apr. 29, 2002).
3. Access to essential drugs requires: (1) rational selection and use of medicine; (2)
sustainable, adequate financing; (3) affordable prices; and (4) reliable health and supply
systems. WHO Medicines Strategy, Expanding Access to Essential Drugs, available at
http://www.who.int/gb/EB-WHA/PDF/EB109/eeb1097.pdf (last visited Oct. 16, 2002); but see
DIANNA MELROSE, BITrER PILLS: MEDICINES AND THE THIRD WORLD POOR 148 (1982)
(describing shortcomings of essential drug lists).
4. Revised Drug Strategy, World Health Assembly, 52nd Sess., Agenda Item 13, at 1, U.N.
Doc. WHA/52.19 (May 24, 1999), available at http://www.who.int/wha-
1998/WHA99/PDF99/e-reso.pdf (last visited Feb. 21, 2002).
5. JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS, REPORT OF THE MEETING ON THE
EVALUATION OF THE UNAIDS HIV DRUG ACCESS INITIATIVE 5 (2000) [hereinafter REPORT ON
UNAIDS INITIATIVE]. Although extended families can provide significant support for many
persons with HIV/AIDS, care remains unaffordable for those lacking family or those whose
families' resources are already depleted.
6. WORLD HEALTH ORGANIZATION, supra note 2.
7. Id.
8. See generally David P. Fidler, Neither Science Nor Shamans: Globalization of Markets and
Health in the Developing World, 7 IND. J. GLOB. LEG. STUD. 191 (1999).
9. See generally PAUL FARMER, INFECTIONS AND INEQUALITIES: THE MODERN PLAGUES,
preface, (1999) (describing disparities in access to TB and HIV drugs in Haiti and Peru and
duty of physicians not to accept lack of resources as a justification for second class care).
10. Alex Duval Smith, AIDS Summit: HIV Judge Attacks Mbeki for Grievous Ineptitude, THE
INDEPENDENT (London), July 11, 2000, at 14 (quoting Judge Edwin Cameron's speech at the
13th World AIDS conference, in which he focused on the high cost of anti-HIV drugs as a
barrier to care in S. Africa and noted, "I exist as a living embodiment of the iniquity of drug
availability in Africa. Amidst the poverty of Africa, I stand before you because I am able to
purchase health and vigour.").
11. The Global Fund to Fight AIDS, Tuberculosis, and Malaria, at
http://www.globalfunddatm.org (last visited Apr. 24, 2002)
3
Lazzarini: Making Access to Pharmaceuticals a Reality: Legal Options Under TRIPS and the Case of Brazil
Published by Yale Law School Legal Scholarship Repository, 2003
YALE HUMAN RIGHTS & DEVELOPMENT L.J.
the first time since the beginning of the epidemic.' 2 Ninety-five percent of
those infected with HIV worldwide live in developing countries,13 and
fewer than five percent have access to effective treatment.14 Unlike in
wealthy countries, AIDS cases and deaths in developing countries have
continued to climb.' 5 The United Nations Joint Programme on AIDS
(UNAIDS) has identified unequal access to affordable treatment as one of
the principal reasons for the drastically lower survival rates in developing
countries.
16
Disparities in access to treatments raise worrisome issues of equity.
Although public health officials have emphasized solidarity among all
people,'7 those living with HIV/AIDS perceive quite the opposite situation:
a dissonant, two-tiered system. Since 1996, in the developed world,
HIV/AIDS has become akin to other treatable chronic illnesses. In the
developing and undeveloped world, it remains a deadly plague.
Differential investment in AIDS prevention mirrors these disparities. In the
mid-1990s, even though more than eighty five percent of infections
occurred in the developing world, only about ten percent of the estimated
$2 billion spent annually on prevention went to slow the spread of HIV
and AIDS in developing countries.1 8 Today, with ninety-five percent of
infections occurring in the developing world, the total funding for
treatment and prevention in the poorest countries hovers around $2
12. HIV and AIDS-United States, 1981-2000, MORBIDITY AND MORTALITY WKLY. REP.
(Centers for Disease Control and Prevention, Atlanta, GA), June 1, 2001, at 430-34, available at
http://www.cdc.gov/ mmwr/preview/mmwrhtml/mm5021a2.htm.
13. The United States Agency for International Development, Global Health, Frequently
Asked Questions, available at http://www.usaid.gov/pop-health/aids/News/aidsfaq.html (last
visited Sept. 23, 2002).
14. Joint United Nations Programme on HIV/AIDS, Press Release, Geneva, 10 September
2002, available at http://www.unaids.org/whatsnew/press/eng/pressarc02/
humanrights 100902.html (last visited Oct. 16, 2002).
15. "In the 45 most affected countries, it is projected that, between 2000 and 2020, 68
million people will die prematurely as a result of AIDS. The projected toll is greatest in sub-
Saharan Africa where 55 million additional deaths can be expected." Joint United Nations
Programme on HIV/AIDS, The Impact of HIV/AIDS, Fact Sheet 2002, available at
http://www.unaids.org/barcelona/presskit/factsheets/FSimpact-en.pdf (last visited Oct. 16,
2002).
16. Joint United Nations Programme on HIV/AIDS, The Report on the HIV/AIDS
Epidemic 142-43 available at http://www.unaids.org/barcelona/presskit/embargo.htm (last
visited Nov. 21, 2002).
17. The slogans of the three most recent International AIDS conferences illustrate the
rhetoric- Vancouver, 1996, "One World, One Hope"; Geneva 1998, "Bridging the Gap"; and
Durban 2000, "Break the Silence." International AIDS Conferences and IAS Conference on
HIV Pathogenesis and Treatment, Previous International AIDS Conferences, available at
http://www.ias.se/page-l.asp?pageld=40 (last visited Oct. 16, 2002). The unfortunate gap
between rhetoric and reality can be seen in the climbing HIV rates around the world and the
falling death rates in the US and Western Europe. See generally JOINT UNITED NATIONS
PROGRAMME ON HIV/AIDS, AIDS EPIDEMIC UPDATE: DEC. 2001, available at
http://www.unaids.org/worldaidsday/2001/Epiupdate2OOl/Epiupdate2OOl-en.pdf (last visited
Oct. 16, 2002).
18. Feminist.corn Women's Feature Service, Women of the World -Statistics (compiled
from U.N. sources), available at http://www.feminist.com/resources/artspeech/inter/
womworldstats.html (last visited Apr. 8. 2002)
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billion.19 While this looks like a substantial increase in spending in the
developing world, spending still falls far below official estimates of $10
billion needed annually to effectively treat HIV/AIDS" and prevent its
spread.20
III. INTELLECTUAL PROPERTY - PREREQUISITE OR BARRIER TO HIV/ AIDS
TREATMENT IN THE DEVELOPING WORLD
Because of the great disparities in access to pharmaceuticals, active
debate surrounds the international legal framework protecting intellectual
property rights. On the one hand, some have argued that patents play little
or no role in limiting access to essential AIDS drugs in Africa.2' On the
other hand, it has been widely reported that some countries have been
reluctant to take any steps that could be interpreted as violating patent and
intellectual property rules. Their uncertainty and fear over possible trade-
related retaliation may deter them (as well as private industry) from
exploiting opportunities for local manufacture or importation of
pharmaceuticals. 22 In this way, the intellectual property system creates
barriers, both perceived and real. 23
19. The Global Fund to Fight AIDS, Tuberculosis, and Malaria, a cooperative international
effort to mobilize both public and private support for efforts to reduce morbidity and
mortality caused by some of the leading deadly diseases, has provided $1.7 billion of this $2
billion. UN Secretary General Kofi Anan has taken on a major role in trying to secure
donations from governments, corporations, foundations and individuals to meet the projected
requirements of the fund. Efforts to Combat Overseas HIV/AIDS: Hearings Before Senate Foreign
Relations Committee, 107th Cong. (Feb. 13, 2002) (statement of Peter Piot, Executive Director,
UNAIDS). "[The Global Fund) supports interventions for the prevention, treatment, care and
support of people with these three diseases." JOINT UNITED NATIONS PROGRAMME ON
HIV/AIDS, GLOBAL FUND FACT SHEET, available at http://www.unaids.org/fact-sheets/files/
fsglobalfund.en.doc (last visited Oct. 16, 2002).
20. The Secretary-General of the United Nations has called for annual funding of the
Global Fund to reach $10.5 Billion by 2005. JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS,
PRESS RELEASE, GENEVA, 10 OCTOBER 2002, available at http://www.unaids.org/whatsnew/
press/eng/pressarc02/globafundlOlOO2_en.html (last visited Oct. 16, 2002). This figure
represents an annual estimate of total funds necessary from all sources, including the Global
Fund, to address HIV/AIDS. A similar estimate to address TB and Malaria is $2 Billion. Global
Fund to Fight AIDS, Tuberculosis and Malaria, Initial Questions on the Global Fund, February
2002, available at http://www.globalfundatm.org/faq-gfund.html#9 (last visited Nov. 23, 2002).
21. Amir Attaran & Lee Gillespie-White, Do Patents for Antiretroviral Drugs Constrain
Access to AIDS Treatment in Africa?, 286 J. Amer. Med. Assoc. 1886, 1886 (2001).
22. Tido von Shoen-Angerer, For Third World Doctors, Lack of Medicine Is a Cning Shame,
S.F. CHRON., June 25, 2000, at 4 (describing Thailand's attempt to allow generic production of
HIV medications, thwarted initially by U.S. pressure and then by fear of estranging foreign
investors); Mukdawan Sakboon, Use Compulsory Licensing, THE NATION (Singapore), Mar. 26,
2000 (describing the threat of compulsory licensing as a factor in Brazil's negotiating discounts
on HIV medications and quoting the WHO's representative in Thailand saying "No poor
nation has ever used compulsory licensing, which is common in America and other
industrialised countries."), at http://www.nationmultimedia.com/page.arcview.php3?
clid=3&id=57572&usrsess=1.
23. Fidler, supra note 8, at 209-14 (arguing that the emerging regime to protect intellectual
property is raising prices and constricting efforts by developing countries to provide
medicines to the poor); Robert Weissman, A Long, Strange TRIPS: The Pharmaceutical Industry
Drive to Harmonize Global Intellectual Property Rules, and the Remaining VVTO Legal Alternatives
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The relationship between patent protection and price is another source
of controversy. Studies demonstrate that the presence of generic drugs
results in lower pharmaceutical prices overall.24 In some developing
countries where patent protections are rare, however, and where local
production capacity is nonexistent, HIV drugs cost more than in western
countries .25
The scope and details of intellectual property protection, especially the
current WTO system, are important for identifying provisions that can both
support and deter access to treatments for residents of poor countries.
A. Patent Protections Pre- and Post-TRIPS
The current World Trade Organization (WTO) system is a very new
phenomenon. It focuses on achieving worldwide uniformity of patent
protections through restrictive patent laws modeled on those of the United
States. Before 1994, both developed and undeveloped countries used a
wide variety of approaches to intellectual property protection, 26 including:
U.S.-style restrictive patents of relatively long duration;27 shorter-term
patents; 28 patents on processes but not products;29 compulsory licensing of
important drugs; 30 requirements that patent holders produce and sell the
drug in the country granting the patent or lose the protection;31 no patent
protection for pharmaceuticals at all (as was the case in Argentina and
Brazil until recently).32
The range of widely varying national laws that existed prior to 1995
results in difficulties:
National patent laws can vary to such an extent that a given
invention may be patentable in one country but not another, be
Available to Third World Countries, 17 U. PA. J. INT'L ECON. L. 1069 (1996).
24. Frederick T. Schut & Peter A.G. Van Bergeijk, International Price Discrimination: The
Pharmaceutical Industry, 14 WORLD DEV. 1141, 1147 (1986) (finding that pharmaceutical prices
drop when countries impose direct price controls, promote use of generics, or abolish patents;
but noting also that the "real" cost of drugs (relative to purchasing power) in many
developing countries is many times higher than in United States).
25. Id.
26. Weissman, supra note 23, at 1071-76 (describing patent policy options used pre-1994).
27. Id. at 1075-77 (1996).
28. MICHAEL J. TREBILCOCK & ROBERT HOWSE, THE REGULATION OF INTERNATIONAL TRADE
310 (2d ed. 2000).
29. Martin J. Adelman & Sonia Baldia, Prospects and Limits of the Patent Provision in the
TRIPS Agreement: The Case of India, 29 VAND. J. TRANSNAT'L L. 507, 520 (1996) (describing
India's recognition of patents for pharmaceuticals processes only, not for pharmaceutical
products).
30. Janet Hamilton, What's Going on in Intellectual Property Law?, 84 AM. SOC'Y INT'L L.
PROC. 256, 258 (1990) (discussing Canada's use of compulsory licensing).
31. Carl Moy, The History of the Patent Harmonization Treaty: Economic Self-Interest as an
Influence, 26 JOHN MARSHALL L. REV. 457, 475-76 (1993).
32. Bruce Rubenstein, Latin America Slow To Protect Patents Under NAFTA, 6 CORP. LEGAL
TIMES 17, (1996) (describing Brazil's reluctance to adopt patent protections); Argentina: No
Patents for Drugs Till 2005, MARKETLETTER, Nov. 7, 1994, at 11 (describing delay in protection
of patents in Argentina).
[Vol. 6
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broadly protected in one country but only narrowly protected in
another, or even be patentable to different persons in different
countries..."Disharmony" [in patent laws across borders] creates
trade barriers and friction at both the private and diplomatic
level.
33
Concerted and sustained lobbying by the pharmaceutical companies 34
succeeded in putting intellectual property issues on the trade agenda
beginning in the 1980s and later established the U.S. model as the preferred
version of patent protection. This version was officially enacted during the
international forum that established the World Trade Organization and
issued the Trade-Related Aspects of Intellectual Property Agreement
(TRIPS).3
The stated purpose of TRIPS includes: "[reducing] distortions and
impediments to international trade.. .and [ensuring] that measures and
procedures to enforce intellectual property rights do not themselves
become barriers to legitimate trade."36 While TRIPS emphasizes the private
right characteristic of intellectual property and the need for a multi-lateral,
multinational framework to protect these rights, it also recognizes the
"special needs of the least-developed country Members in respect of
maximum flexibility in the domestic implementation of laws and
regulations in order to enable them to create a sound and viable
technological base." 37 Countries that are party to the treaty have bound
themselves to protect all products and processes against use, sale, import,
or manufacture without the permission of the patent holder, except under
very specific circumstances. 38 TRIPS demands that countries enforce
patents for twenty years from the date of filing.39 When a patent holder
suspects a manufacturer of using a patented process to manufacture a
product which appears identical to one made by the patent holder, TRIPS
assigns the burden of proof for showing that the product did not infringe
the patent on its manufacturer rather than on the holder of the patent.
40
33. Donald S. Chisum, Introduction, 26 JOHN MARSHALL L. REV. 437, 438 (1993).
34. See Weissman, supra note 23, at 1075-77.
35. See Agreement on Trade-Related Aspects of Intellectual Property Rights, art. 21, Apr.
15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex IC, Legal
Instruments-Results of the Uruguay Round Vol. Ic. 31, 33 I.L.M. 81 (1994)[hereinafter TRIPS].
36. Id., pmbl.
37. Id., pmbl.
38. Article 28, paragraph 1 of TRIPS describes the rights of a patent holder as follows:
A patent shall confer on its owner the following exclusive rights: (a) where the
subject matter of the a patent is a product, to prevent third parties not having
his consent from the acts of: making, using, offering for sale, selling, or
importing for these purposes that product; (b) where the subject matter of a
patent is a process, to prevent third parties not having his consent from the act
of using the process, and from the acts of: using, offering for sale, selling, or
importing for these purposes at least the product obtained directly by that
process.
Id. art. 28 (internal citations omitted).
39. Id. art. 33.
40. Id. art. 34.
20031
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B. Will Strong Universal Patent Protection Decrease or Increase Access to
Pharmaceuticals?
One of the chief arguments for patent protections in general is the need
to encourage innovation and risk-taking, which are necessary for the
successful development of new drugs.41 In fact, some scholars assert that
the establishment of property rights (including intellectual property) and
economic development in western countries have a clear, consistent, and
even causative relationship.
42
Rapp and Rozek, for example, refer to data relating degrees of patent
protection to levels of development and find a close correlation between
strong patent protections and high economic growth and levels of
development.43 They argue that the overall costs to the economy of failing
to protect patents (low levels of development and growth) outweigh the
benefits (temporarily easier access to pharmaceuticals). They also assert
that by failing to protect patents in pharmaceuticals, countries risk having
"fewer new pharmaceutical products, reduced fuiure growth of the
domestic industry and, most importantly, poorer health for the country's
residents."4
Supporters of strong patent protection often overlook the potential
harms that higher prices will have on countries' citizens and public health.
Singham addresses this concern directly, arguing that increased patent
protection will neither raise prices nor be harmful to consumers because
the numbers of drugs going off patent will be matched by the number of
new patented (more expensive drugs). The problem with this argument is
that it assumes that older drugs will meet the needs of "consumers" just as
well as new ones.45 This is clearly not the case with HIV medications: The
very reason people with HIV are so anxious to gain access to the newest
41. See, e.g., T.W. Roberts, Letter to the Editor, Cost of Drugs to the Third World, THE TIMES
(London), Dec. 10, 1999 (arguing that drug company patents and high prices are necessary to
support drug development and to allow companies to recoup investment.); The Poor Need
Medicines, but the Drug Industry Is Not a Global Charity, THE INDEPENDENT (London), Mar. 6,
2001, at 3 (arguing that the international system should be able to design and enforce a
workable system of tiered pricing or to streamline the approval process of new drugs to
reduce development costs and speed them to market albeit with greater risks); Deborah
Hope, Drug Patents Cause World Legal Fevers, THE WEEKEND AUSTRALIAN, Mar. 2, 2002, at 30
(quoting GlaxoSmithKine spokesman Phil Thomson's statement that "patents do not block
medicines. They stimulate research").
42. See, e.g., Richard T. Rapp & Richard P. Rozek, Benefits and Costs of Intellectual Property
Protection in Developing Countries, J. WORLD TRADE 75 (Oct. 1990); Shanker A. Singham,
Symposium: Third Annual Latin American Competition and Trade Round Table: Competition Policy
and the Stimulation of Innovation: TRIPS and the Interface Between Competition and Patent
Protection in the Pharmaceutical Industry, 26 BROOK. J. INT'L L. 363, 372-79 (2000) (asserting an
important relationship between strong patent protection laws in a country and high levels of
investment in research and development and between strong patent protection and economic
growth).
43. Rapp & Rozek, supra note 42, at 77-81.
44. Id. at 86.
45. Singham, supra note 42, at 386-87.
[Vol. 6
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drugs is bften that the new drug is a necessary part of combination
therapy, because they need the new drug as an alternative to regimens that
have been exhausted or to avoid serious side-effects.
Not all commentators agree that universal, strong patent protections
are necessarily related to economic benefits. Some suggest that strong
property protections can actually deter innovation by discouraging
researchers from pursuing new products or processes that entail using one
or more patent-protected materials. 46 Others argue that while countries
with advantages in innovation, strong research infrastructure, and a
tendency to "export information" -that is technical discoveries and
innovations -will benefit from patent protections, those without those
characteristics (mostly poorer countries) will be harmed by stronger
protections.
47
The degree to which patent protection and high prices are necessary to
support research and development has been questioned.48 Not only is the
pharmaceutical industry consistently one of the most profitable
industries, 49 but also those pharmaceutical firms that ranked among the
Fortune 500 companies also devoted less of their total revenue to research
and development of new drugs (R&D) (12.5 percent) than to profits (18.5
percent) or marketing and administration (30.4 percent).50
Even if high prices encourage R&D, they are not the only means of
46. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCIENCE 698 (1998); Steve Bunk, Researchers Feel
Threatened by Disease Gene Patents, THE SCIENTIST 7 (Oct. 11, 1999).
47. Trebilcock and Howse argue that strengthened intellectual property protection might
increase the economic welfare of certain information exporting countries, stronger protections
in countries that lack a strong manufacturing sector or rely on imitation in manufacturing
information importing countries might reduce economic welfare. They also relate the
argument of Allan Deardorff that "global aggregate welfare may well be maximized if certain
countries are exempted completely from requirements for intellectual property protection. The
reason is that with respect to these poorer countries, the marginal increased rents to the patent
holder are unlikely to be substantial enough to constitute significant incentives to further
innovation. However, the losses to developing countries from being forced out of imitation or
buying imitations from elsewhere would probably be more substantial." TREBILCOCK &
HOwSE, supra note 28, at 310.12 (quoting Allan Deardorff, Should Patent Protection Be Extended
to All Developing Coun tries?, 13 WORLD ECONOMY 497-508 (1990)).
48. J. Love & J. Davids, Property, Production, and Politics: Identifying the True Cost of Drug
Development and Production and Clarifying TRIPS, XIII Int'l Conf. on AIDS, July 9-14, 2000
Abstract no. TuPpE1210; D. Palmer et al., Challenging International Trade Policy-Democratizing
Access to Medicines Globally, XIII Intl. Conf. on AIDS. July 9-14, 2000 Abstract no. TuOrE457.
49. PUBLIC CITIZEN, PHARMACEUTICALS RANK AS MOST PROFITABLE INDUSTRY AGAIN:
"DRUGGERNAUT" ToPs ALL THREE MEASURES OF PROFITS IN NEW FORTUNE 500 REPORT (Apr.
17, 2002) (noting that the pharmaceutical industry ranked first in all three measures of
profitability due to higher pill prices, high levels of advertising, and less spending on R&D),
available at http://www.citizen.org/congress/reform/drug-industry/profits/articles.cfm?ID=
7416.
50. Id. at graphs 4-5 (illustrating the proportion of revenues of Fortune 500 Drug
Companies going into R&D, profits, marketing and administration, and the comparison
between profits and R&D investment for the ten most profitable Fortune 500 Drug Companies
in 2001); PUBLIC CITIZEN, Rx R&D MYTHS: THE CASE AGAINST THE DRUG INDUSTRY'S R&D




Lazzarini: Making Access to Pharmaceuticals a Reality: Legal Options Under TRIPS and the Case of Brazil
Published by Yale Law School Legal Scholarship Repository, 2003
YALE HUMAN RIGHTS & DEVELOPMENT L.J.
increasing R&D. 51 Governments could provide additional funding for R&D
or, through international agreements, mandate public and corporate
contributions to multi-national R&D funds. They could use general tax
revenues or tax profits on drugs aimed primarily at developed world
consumers to support R&D in "tropical" diseases, which primarily affect
residents of developing countries.52 A variation on this option -voluntary
partnerships between governments, international organizations, private
companies and researchers -exists in a limited form to address the need
for more sustained research on tropical diseases.53
C. TRIPS: Constraints and Flexibility
As stated above, TRIPS was drafted following extensive lobbying by
international pharmaceutical manufacturers and reflects many values
favorable to large multi-national corporations. By establishing a set of rules
that requires all countries to provide uniform patent protections to all
intellectual property products and processes, it tightens the screws on
those countries, including many developing countries, that try to avoid
adopting U.S.-style patent protections.
TRIPS does offer some flexibility to developing countries moving from
weaker to stronger intellectual property regimes, however, by delaying the
entry into force of the requirements for TRIPS-compliant provisions in
developing countries and by providing specific and general exceptions that
could be used by developing countries to increase access 54 and to protect
public health or the environment.
The terms of TRIPS allow at least four exceptions that would permit
developing countries to increase access while remaining compliant; it
allows a country to (1) exclude products from patent protection where
necessary to protect public health and the environment;55 (2) create limited
exceptions to patents, provided the country can show that the interests of
the patent owner are not unreasonably infringed upon;56 (3) issue
compulsory licenses subject to certain restrictions;57 and (4) impose price
controls and taxes that do not discriminate between domestic and
imported goods, which can be waived if the patent holder will license its
product or process non-exclusively.58 The efficacy of these exceptions will
depend on how courts interpret them and balance the' interests of patent
51. JAMES LOVE, PAYING FOR HEALTH CARE R&D: CARROTS AND STICKS (Oct. 19, 2001)
(describing mechanisms available to governments to enhance R&D efforts), available at
http://www.cptech.org/ ip/health/md/carrotsnsticks.html (last visited Apr. 21, 2002).
52. Weissman, supra note 23, at 1072-75.
53. Richard J. O'Brien & Paul P. Nunn, The Need for New Drugs Against Tuberculosis:
Obstacles, Opportunities, and Next Steps, 163 AM. J. OF RESPIRATORY AND CRITICAL CARE
MEDICINE 1055-58 (2001), available at http://ajrccm.atsjoumals.org/cgi/reprint/163/5/1055.pdf.
54. TRIPS, supra note 35, art. 27, 9J9J 2, 34.
55. Id., art. 27.
56. Id., art. 30.
57. Id., art. 34.
58. Weissman, supra note 23. at 1098.
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holders, developing countries, and third parties.59
D. Indigenous Rights and Intellectual Property
The emerging area of indigenous peoples' rights also provides
opportunities to re-define how and when intellectual property will be
protected and how access to benefits will be guaranteed. 60 Modern
intellectual property protections have often disfavored the types of
knowledge most commonly held and valued by indigenous peoples. The
requirements for novelty of invention and description of the patentable
item by an identifiable creator have made much indigenous knowledge
difficult to patent and therefore vulnerable to use or exploitation by
others.61 In fact, some writers claim that intellectual property, as it is
currently conceptualized, promotes "biocolonialism" -the appropriation
and conversion of biologically or genetically unique information from
indigenous cultures to private intellectual property, largely for the benefit
of western pharmaceutical and seed companies. 62 Indigenous peoples
themselves have reportedly expressed widespread dissatisfaction with
western intellectual property schemes because of their failure to recognize
and protect much of what is important to their cultures.63
Others, however, see new developments in intellectual property and
science as assets to indigenous peoples' rights movements and as
opportunities for these peoples to protect their heritage while accruing
economic benefit. A working group on indigenous peoples' rights
enunciated this claim as follows:
Indigenous peoples are entitled to the recognition of the full
ownership, control and protection of their cultural and intellectual
property.
They have the right to special measures to control, develop and
protect their sciences, technologies and cultural manifestations,
including human and other genetic resources, seeds, medicines,
knowledge of the properties of fauna and flora, oral traditions,
literatures, designs and visual and performing arts.64
59. Id. at 1100-15.
60. Rosemary J. Coombe, Intellectual Property, Human Rights & Sovereignty: New Dilemmas
in International Law Posed by the Recognition of Indigenous Knowledge and the Conservation of
Biodiversity, 6 IND. J. GLOBAL LEGAL STUD., 59, 77-82 (1998).
61. Audrey R. Chapman, Approaching Intellectual Property as a Human Right: Obligations
Related to Article 15 (1) (c), U.N. ESCOR, Comm. on Econ. Soc. and Cultural Rts., 24th Sess., at
9] 25, 33, 44, U.N. Doc. E/C. 12/2000/12 (2000); Fidler, supra note 8, at 212-13.
62. Laurie Anne Whitt, Part One: Interdisciplinary Perspective: Indigenous Peoples, Intellectual
Property & the New Imperial Science, 23 OKLA. CITY U.L. REV. 211, 214-15 (1998).
63. David J. Stephenson, Symposium: Sixth Annual Tribal Sovereignty Symposium: The Nexus
Betzoeen Intellectual Property Piracy, International Law, the Internet, and Cultural Values, 14 ST.
THOMAS L. REV. 315, 318-19 (2001).
64. Draft Declaration on the Rights of Indigenous Peoples, U.N. ESCOR, Comm. on Hum. Rts.,
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Whitt asserts that one solution is for indigenous communities to
develop alternatives to western-style intellectual property standards.
Possibilities include: "community intellectual property," which would
allow communities, instead of individuals, to identify and protect from
expropriation knowledge and resources that had existed for generations;
an "inalienability of cultural property," which would protect the heritage
for future generations of the community; and extensions of conventional
copyright allowing protection of intangible expressions (including genetic
resources).65 Others argue that indigenous peoples and nations with large
indigenous populations ought to use the mechanisms available through
TRIPS to extend protection to valuable national and local resources. 66
Another approach sees international human rights provisions as tools to
modify intellectual property rights claims, ensuring that the rights and
interests of indigenous peoples are protected, even though their interests
differ from the dominant culture.
67
The use of human rights principles to reconstruct copyright laws that
protect indigenous peoples' heritage is one example of how human rights
can work as a framework for resolving intellectual property issues. The
campaign of indigenous peoples for more flexibility in intellectual property
doctrine resonates with the claims of public health advocates and persons
with HIV/AIDS in the developing world.
E. Other Barriers to Access to Pharmaceuticals
High prices or protectionist laws are not the only barriers to providing
high quality HIV care in the developing world. Both advocates and
opponents of treatment access agree that there are other obstacles to high
quality care in the developing world.68 Persistent barriers include the lack
of public health infrastructure to provide testing, counseling, disease
surveillance, and partner notification programs. Most developing countries
also have a shortage of clinicians and facilities experienced in providing
anti-retroviral treatment and monitoring patients for adherence and side
effects. They also lack other social services including drug treatment,
mental health care, and prevention education.69
65. Whitt, supra note 62, at 255-57.
66. TREBILCOCK & HOWSE, supra note 28, at 334 (claiming that TRIPS offers nations the
potential to protect genetic resources of biodiversity via patent or other national restrictive
laws).
67. Stephenson, supra note 63, at 331-32.
68. See Zackie Achmet, Commentary: Most South Africans Cannot Afford Anti-HIV Drugs, 324
BRIT. MED. J., 214-18 (2002) (arguing that patent laws prohibiting the production of generic
antiretroviral drugs keep prices out of the reach of most South Africans); Donald Berwick,
"We All Have AIDS": Case for Reducing the Cost of HIV Drugs to Zero, 324 BRIT. MED. J. 214-18
(2002) (recounting the story of how an editorial demanding that the price of HIV drugs be
reduced received no response from pharmaceutical companies); Richard Sykes, Commentary:
The Reality of Treating HIV and AIDS in Poor Countries, 324 BRIT. MED. J. 214-18 (2002)
(discussing the need to develop infrastructure to distribute price-reduced drugs).
69. REPORT ON UNAIDS INITIATIVE. supra note 5, at 2(!iti ng brrier tf nbtamin; gH-
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Structural barriers also influence the quality and nature of HIV
prevention and care services.70 Structural factors negatively influencing
HIV care and prevention include low levels of economic development,
frequent population migrations, political instability, gender inequality,
drug policies that promote risky behavior or further marginalize drug
users, and laws and policies that maintain any of these conditions.71 The
largest barrier, however, may be the political inertia among governments
with limited resources to make public health, equity, and specifically,
treatment of HIV/ AIDS, priority issues.72
Although these barriers seem substantial, they should not dissuade
countries from taking steps toward providing more widespread access to
pharmaceuticals. Providing HIV/AIDS treatment may have important
collateral benefits, such as spurring development of a public health
infrastructure, preserving the working abilities of many affected
professionals, and providing hope to individuals and families affected by
HIV/AIDS.73
IV. ACCESS TO PHARMACEUTICALS AS A HUMAN RIGHT
The HIV/AIDS epidemic has shaped how advocates think of health
and human rights and how they approach their work. Early in the
epidemic, public health officials and advocates acknowledged the potential
role of human rights and included recognition of that role in international
and national strategies. 74 Officially, human rights language has been
integrated into most international and national HIV/AIDS strategies
developed in the last decade. 75 Unfortunately, realization of human
related drugs); Barbara Crossette, Poor African Countries Lack Ways to Monitor Use of New AIDS
Drugs, Experts Warn, N.Y. TIMES, Apr. 1, 2001 (describing challenges to providing HIV
treatment safely in countries with poor health infrastructure); GALEN to Assist Safe
Introduction of ARV Drugs, U.S. NEWSWIRE, Apr. 9, 2001 (reporting that the International
Association of Physicians in AIDS Care (LAPAC) argue successful HJV treatment faces many
other obstacles besides the high price of drug treatment).
70. Kim M. Blankenship et al., Structural Interventions in Public Health, 14 AIDS S11 (suppl.
1) (2000).
71. Richard G. Parker et al., Structural Barriers and Facilitators in HIV Prevention: A Review of
International Research, 14 AIDS S22 (Suppl. 1) (2000).
72. All governments can claim to have limited resources-either because the country is
poor in an absolute sense, or because government policies prioritize tax reduction over public
spending.
73. Piot, supra note 19.
74. World Summit of Ministers of Health, London Declaration on AIDS Prevention, WHO Doc.
WHO/GPA/INF/88.6 (Jan. 28, 1987); Global Strategy for the Prevention and Control of AIDS,
World Health Assembly Res. WHA 40.26 (May 5, 1987), available at
http://www.aidslaw.ca/Maincontent/otherdocs/Newsletter/vol6nosl-
22001/discrimination.htm (last visited Oct. 16, 2002); Avoidance of Discrimination in Relation to
HIV-infected People and People with AIDS, World Health Assembly Res. WHA 41.24 (May 13,
1988).
75. Guidelines on HIVIAIDS and Human Rights as Adopted by the Second International
Consultation on HIVIAIDS and Human Rights, Report of the Secretary General, Second
International Consultation on HIV/AIDS and Human Rights (Geneva, Sept. 23-25, 1996), at 11,
U.N. Doc. E/CN.4/1997/37 (1997).
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rights - meaning both countries' success in guaranteeing fundamental
human rights and their embrace of a human rights perspective on
HIV/ AIDS -often lags far behind the rhetoric of the official strategies.
An innovative yet elusive assertion that has emerged from the early
years of the health and human rights movement is the argument that
realization of human rights is a necessary pre-condition to good health.76
Social epidemiologists have observed that fundamental determinants of
health, which are often distinct from traditional "health indicators," shape
the health of populations and thus impact the health of individuals within
that population.77 These fundamental determinants of health include
income, socio-economic status, social capital, social cohesion, and
race/racism. 78 Jonathan Mann and others applied similar analysis using
indicators of human rights. Their argument was most persuasive when
considering the particular vulnerability of women and other groups to
HIV. 79 In societies in which women have secondary social and legal status
to men, where they are usually dependent on men for economic security,
and where it is culturally prohibited for women to question men's sexual
activity or to control when and how they have sex, even comprehensive
public health education and provision of condoms will not reduce
women's risk of infection with HIV (or STDs, or many other diseases).
Women will not be able to use health information fully to protect
themselves and their children until they have equal realization of their
human rights, both legal and actual.
80
Activists throughout the world make similar arguments for the
necessity of realization of human rights in relation to access to
pharmaceuticals. They argue that without governments' commitment to
promote and ensure sharing medical technology at least as vigorously as
they have pledged to protect intellectual property rights under TRIPS, the
poor in many nations will never achieve good health.
A. Foundation in International Human Rights Instruments
76. Jonathan Mann et al., Health and Human Rights, 1 HEALTH AND HUMAN RIGHTS 6, 19-22
(1994).
77. See Lisa F. Berkman & Ichiro Kawachi, A Historical Framework for Social Epidemiology, in
SOCIAL EPIDEMIOLOGY 3-12 (Lisa F. Berkman & Ichiro Kawachi, eds., 2000) [hereinafter SOCIAL
EPIDEMIOLOGY]; Michael Marmot, Multilevel Approaches to Understanding Social Determinants, in
SOCIAL EPIDEMIOLOGY, supra, 349, 353; Geoffrey Rose, Sick Individuals and Sick Populations, 14
INT'L J. OF EPIDEMIOLOGY, 32-38 (1985); GEOFFREY ROSE, THE STRATEGY OF PREVENTIVE
MEDICINE (1992).
78. John Lynch & George Kaplan, Socioeconomic Position, in SOCIAL EPIDEMIOLOGY, supra
note 77, at 13-35; Nancy Krieger, Discrimination and Health, in SOCIAL EPIDEMIOLOGY, at 36-75;
Ichiro Kawachi, Income Inequality and Health, in SOCIAL EPIDEMIOLOGY, at 76-94; Lisa F.
Berkman & Thomas Glass, Social Integration, Social Networks, Social Support, and Health, in
SOCIAL EPIDEMIOLOGY, at 137-73; Ichiro Kawachi & Lisa Berkman, Social Cohesion, Social
Capital and Health, in SOCIAL EPIDEMIOLOGY, at 174-90.
79. Jonathan Mann & Sofia Gruskin, Women's Health and Human Rights: The Health and
Human Rights Movement, 1 HEALTH AND HUMAN RIGHTS 309, 309-66 (1995); LAWRENCE 0.
GOSTIN & ZITA LAZZARINI, HUMAN RIGHTS AND PUBLIC HEALTH IN THE AIDS PANDEMIC (1997).
80. GOSTIN & LAZZARINI. id. at 46.
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A careful reader will find. no "right to access to pharmaceuticals" in the
International Bill of Human Rights or in any subsequent modem human
rights instruments. However, such an obligation -although not a defined
human right itself-is firmly grounded in the implications of existing
substantive provisions and in the special needs created by the current
circumstances.
International human rights instruments provide legal support for a
right to access to treatment as part of existing human rights law and
suggest possible ways to reconcile apparently conflicting interests of
commerce and public health. These instruments include several provisions
that are highly relevant to access to pharmaceuticals. Both the Universal
Declaration of Human Rights (UDIR) and the International Covenant on
Economic, Social, and Cultural Rights (ICESCR) incorporate provisions
guaranteeing the right to health. Specifically, the UDHR states, "Everyone
has the right to a standard of living adequate for the health and well-being
of himself and of his family, including.. .medical care and necessary social
services, and the right to security in the event of...sickness, disability,
widowhood, old age or other lack of livelihood in circumstances beyond
his control."81 The ICESCR makes the right more explicit: 'Lthe right to...the
highest attainable standard of physical and mental health.8 2 The ICESCR
also obligates states to take steps necessary to achieve "prevention,
treatment and control of epidemic, endemic, occupational and other
diseases..." 83 and "creation of conditions which would assure to all medical
service and medical attention in the event of sickness."84
The same documents guarantee the right to share in the benefits of
science and technology. The UDHR states, "Everyone has the right freely to
participate in the cultural life of the community, to enjoy the arts and to
share in scientific advancement and its benefits..."8 5 and "the right to the
protection of the moral and material interests resulting from any scientific,
literary or artistic production of which he is author."8 6 The ICESCR
provides: "the right to take part in cultural life"8 7 ; "the right to enjoy the
benefits of scientific progress and its applications"88; and "the right to
benefit from the protection of the moral and material interests resulting
from any scientific, literary or artistic production of which he is the
author."89 Notably, both the UDHR and ICESCR combine within the same
article the right to protection of "authors"' rights in the property interests
from their creations and the right to share in the benefits of scientific
81. Universal Declaration of Human Rights, art. 25.1, G.A. Res. 217A(III), U.N.GAOR, 3d
Sess., at 71, U.N. Doc. A/810 (1948) [hereinafter UDHR].
82. International Covenant on Economic, Social, and Cultural Rights, art. 12.1, G.A. Res.
2200A(XXI) U.N. GAOR, Supp. No. 16, at 49, U.N. Doc. A/6316 (1966), reprinted in 6 I.L.M.
360 [hereinafter ICESCRI.
83. Id., art. 12.2.c.
84. ICESCR, supra note 82, art. 12 § 1, T d.
85. UDHR, supra note 81, art. 27 § 1.
86. Id., art. 27 § 2.
87. ICESCR, supra note 82, art. 15 § 1, 9T a.
88. Id., art. 15 § 1, 9 b.
89. Id., art. 15 § 1, 9 c.
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advancement. 90
Finally, the UDHR also protects the right to life: "Everyone has the
right to life, liberty and security of person."91 The International Covenant
on Civil and Political Rights (ICCPR) incorporates the right to life by
stating: "Every human being has the inherent right to life. This right shall
be protected by law. No one shall be arbitrarily deprived of his life." 92
Importantly, pursuant to the ICESCR, each nation agreed to "take steps
individually and through international assistance and cooperation,
especially economic and technical, to the maximum of its available
resources, with a view to achieving progressively the full realization of the
rights recognized in the present Covenant by all appropriate means,
including particularly the adoption of legislative measures." 93
Tensions between sharing and protecting substantive information
about scientific advances and between national responsibility for human
rights and international obligations of rich countries to poorer ones are
built into the fiber of the UDHR and the ICESCR. Resolving these tensions
requires balancing the conflicting goals and carefully navigating
international rules regarding trade and intellectual property. It also
requires recognition of the fact that in the era of modern public health and
medicine, access to the benefits of scientific advances, including the best
means of prevention and treatment, is inextricably bound up with
individuals' ability to realize their rights to health and life. 94
Even if we were not able to find specific legal means of addressing
questions of access to pharmaceuticals within the human rights legal
framework, the current status of public health needs around the world
suggests that access is clearly a human rights issue in the broadest sense.
The United Nations Charter and the Universal Declaration of Human
Rights express broad notions of social justice and equality of dignity and
rights that go beyond the individual rights enumerated in the specific
human rights instruments. Along with the ICESCR and the ICCPR, they
form the foundations of international human rights law.95 Significantly, the
90. See also id. art. 15 § 2 ("The steps to be taken by the States Parties to the present
Covenant to achieve the full realization of this right shall include those necessary for the
conservation, the development and the diffusion of science and culture."); art. 15 § 3 ("The
States Parties to the present Covenant undertake to respect the freedom indispensable for
scientific research and creative activity."); art. 15 § 4 ("[T]he States Parties to the present
covenant recognize the benefits to be derived from the encouragement and development of
international contacts and cooperation in the scientific and cultural fields.").
91. UDHR, supra note 81, art. 3.
92. International Covenant on Civil and Political Rights, adopted Dec. 19, 1966, S. Exec.
Doc. E, 95-2, art. 6, 1, 999 U.N.T.S. 171 [hereinafter ICCPRI.
93. Id., art. 2, 1 1.
94. Paul Farmer et al, Community-Based Approaches to Hil Treatment in Resource-Poor
Settings, 358 LANCET 404 (2001).
95. The United Nations Charter applies to all member states, including the United States,
but is concerned mostly with the founding of the United Nations and less with articulating
specific human rights norms or obligations. The UDHR is non-binding on its signatories
because it is a declaration rather than a convention or treaty. The degree of international
acceptance of the UDHR has been so great, however, that it has achieved the status of
"customarv international law" with it. f- fpplile 11 1 -er states. 1-,D ..ATI. AL
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U.N. Charter and the UDHR also illustrate the use of human rights as a
"mode of moral reasoning rooted in or articulating a vision of the good in
social relations." 96 In this context, the current gross disparities in access to
medicines, health outcomes, and investment of resources seem
fundamentally unfair.
B. Support in Other Sources of Law
A wide range of other international and domestic provisions relate to
access issues. First, and perhaps foremost in legal advocacy efforts, are
those domestic laws and constitutions that have incorporated human rights
into the substantive rights guaranteed to their people.97 Such legal
provisions can form the theoretical and procedural basis for local efforts to
enforce individual human rights using advocacy and the court system.
Actual realization of human rights through domestic provisions depends,
of course, on a relatively strong and independent judiciary and
government resources to back any finding of obligation.
International and national codes of research ethics that mandate
consideration of distributive justice issues support requiring access to new
pharmaceuticals at least to those subjects or groups who have participated
in the research. 98 While codes of research ethics do not make any claims to
HUMAN RIGHTS 617 (Frank Newman & David Weissbrodt eds., 1990) (noting that the UDHR is
"widely acknowledged as reflecting binding norms of customary international law....").
Although the United States played an important role in drafting the ICESCR and the ICCPR, it
has ratified only the ICCPR. Thus, while the legal obligations stemming expressly from the
ICESCR do not apply to the United States, the broad obligations to respect, protect, and fulfill
the whole range of human rights contained in the UDHR and alluded to in the U.N. Charter
do apply.
96. Scott Burris, Introduction: Merging Law, Human Rights and SocialEpidemiology, 30 J. OF L.,
MEDICINE & ETHICS 498, 502 (2002).
97. See Janet Koven Levit, The Constitutionalization of Human Rights in Argentina: Problem or
Promise?, 37 COLUM. J. TRANSNAT'L L. 281, 292-302 tbl. 1 (1999) (describing incorporation of
human rights substantive norms into constitutions across Latin America and the exclusions
and limitations of such internalization); THE RIGHT TO HEALTH IN THE AMERICAS: A
COMPARATIVE CONSTITUTIONAL STUDY (Hemn L. Fuenzalida-Puelma & Susan Scholle
Connor eds., 1989) (describing efforts to incorporate the "right to health" into Latin American
Constitutions); Hector Fix-Fierro & Sergio Lopez-Ayllon, The Impact of Globalization on the
Reform of the State and Lazv in Latin America, 19 HOUS. J. INT'L L. 785, 797-99 (describing
acceptance of jurisdiction of the regional Inter-American Court of Human Rights by 14
countries and the incorporation of human rights norms into constitutions in a number of
countries, including El Salvador, Argentina and Paraguay).
98. NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL
RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION
OF HUMAN SUBJECTS OF BIOMEDICAL AND BEHAVIORAL RESEARCH, Part B, § 3 (U.S. Department
of Health Education and Welfare, 1979) ("[Wihenever research supported by public funds
leads to the development of therapeutic devices and procedures, justice demands both that
these not provide advantages only to those who can afford them and that such research
should not unduly involve persons from groups unlikely to be among the beneficiaries of
subsequent applications of the research."), available at http://ohrp.osphs.dhhs.gov.
humansubjects/guidancelbelmont.htm (last visited Apr. 26, 2002) [hereinafter BELMONT
REPORT] ; WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: ETHICAL PRINCIPLES FOR
MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS 19, 30 (1964) ("Medical research is only
justified if there is a reasonable likelihood that the populations in which the research is carried
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act as tools to resolve larger human rights issues, their basic premise that
the benefits and burdens of research should be fairly distributed 99 strongly
supports the idea that individuals and groups who bear the burdens of
research should be provided an opportunity to benefit from the results of
that research. Thus, study sponsors have an obligation to those individuals
and groups who willingly undertake the risks of research -unanticipated
harms, unpleasant or dangerous side effects, or failure of study regimens
or devices-to ensure that the subjects receive new treatments or
interventions discovered in the course of the study. This obligation has
implications both for short-term individual studies and the long-term
obligations of governments, institutions, and private entities pursuing
health research in the developing world.
Parties to the General Agreement on Tariffs and Trade (GATT) have
agreed on principles of sustainable development that foster protection of
the environment, growth of domestic industries for essential goods and
services, and the creation of domestic infrastructure. 100 These goals
arguably include bolstering a country's ability to manufacture medicines
needed to treat significant public health problems. Moreover, international
agreements regarding the interpretation of treaties and trade agreements
indicate that states' obligations under human rights should take
precedence over other international agreements.101 Finally, trade
agreements themselves allow states to act to protect the public health 102
and to promote sectors vital to their development, as well as to prevent
"abuse of patents" that unreasonably restrain trade and the transfer of
intellectual property. 103
V. RECONCILING CONFLICTS, FINDING POSSIBLE SOLUTIONS
This section considers possible ways to reconcile the potentially
conflicting demands of two bodies of international law -human rights and
intellectual property provisions-that are crucial to the debate over access
to pharmaceuticals in poor countries. International human rights law
emphasizes the primary values of respecting human dignity, enhancing
out stand to benefit from the results of the research... At the conclusion of the study, every
patient entered into the study should be assured of access to the best proven prophylactic,
diagnostic and therapeutic methods identified by the study."), available at
http://www.med.umich.edu/irbmed/FederalDocuments/hhs/ HHS45CFR46. html#46.401
[hereinafter DECLARATION OF HELSINKI]; COUNCIL OF INTERNATIONAL ORGANIZATIONS OF
MEDICAL SCIENCES (CIOMS) INTERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH
INVOLVING HUMAN SUBJECTS guidelines 5, 10, 12, 21 (Jan. 2002), available at
http://www.cioms.ch/ guidelines january_2002.htm (last visited Apr. 26, 2002) [hereinafter
CIOMS GUIDELINES].
99. BELMONT REPORT, supra note 98, IT 19, 30; CIOMS GUIDELINES, supra note 98, at
guideline 12.
100. Marrakesh Agreement, supra note 35, pmbl. (referring to member countries'
commitment to sustainable development).
101. Vienna Convention on the Law of Treaties, May 22, 1969, 1155 U.N.T.S. 331, 8 I.L.M.
679.
102. TRIPS, supra note 35, art. 27, 1 2.
103. Id., art. 8, 91 2.
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health, and promoting the right to life, while infringing on other rights as
little as possible. From intellectual property provisions we may draw on
the full range of exceptions to patent protection allowed under TRIPS, as
well as the power of states to tax, use price controls, and adopt tiered
pricing. Additionally, potential solutions ought to include other strategies,
such as governments negotiating agreements with pharmaceutical
companies for donations or discounts, undertaking brokered deals for
purchase of generics, and seeking debt cancellation under specific new
programs. Finally, some would suggest that more radical solutions ought
to be considered, even if they are not ultimately necessary.
A. Human Rights as a Framing Mechanism
Article 15 of the ICESCR establishes a framework for intellectual
property rights in three related paragraphs. At the same time, however, the
article poses the difficult challenge of how to interpret, prioritize, and
reconcile the seemingly conflicting rights contained within it. Article 15
asserts that " [t]he States Parties to the present Covenant recognize the right
of everyone ...To take part in cultural life...to enjoy the benefits of scientific
progress and its applications... [and] To benefit from the protection of the
moral and material interests resulting from any scientific, literary or artistic
production of which he is the author." 104
These rights have a meaning and context within the Covenant itself, as
well as in the larger realm of international legal provisions relating to the
same subjects. Both the UDHR and the ICESCR address these rights in the
same article, which suggests that the drafters intended them to be linked
and reconciled-or at least balanced. 10 5 A balanced interpretation would
neither abolish intellectual property protections nor unduly infringe on the
right of people to benefit from scientific innovations. Rather, such an
interpretation would recognize both the importance of protecting
intellectual property for the promotion of new marketable drugs and of
allowing states to take reasonable steps to protect and preserve public
health by making important drugs affordable and available. 10 6 A middle
ground that preserves and maximizes both interests would represent an
appropriate and balanced interpretation of the drafters' goals.
Human rights instruments, such as the ICESCR 07, recognize that many
104. ICESCR, supra note 82, art. 15, § 1, 11 a-c.
105. Chapman, supra note 61, 9191 19-24 (examining record of the drafting of Article 27 of
the UDHR and Article 15 of the ICESCR and the adoption of the ICESCR to show that
delegates intended all three provisions to be seen as interrelated and that recognition of each
was essential to full enjoyment of all).
106. World Health Organization, Statement by the World Health Organization on the Outcome
of the World Trade Organization's Doha Ministerial Conference, Nov. 15, 2001 (expressing pleasure
with WTO ministers' clear conclusion that the TRIPS agreement "can and should be
interpreted and implemented in a manner supportive of WTO members' rights to protect
public health and, in particular, promote access to medicines for all."), at
http://www.who.int/inf-pr-2001/en/state200l-18.html (last visited Apr. 21, 2002); WHO
Medicines Strategy, supra note 3.
107. The ICESCR provides,
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of the rights contained in them are not absolute and must necessarily be
limited under certain circumstances in order to protect other rights or to
preserve the overall intention of the documents. 108 For example, although
the right to protection of property is important for full realization of the
rights protected by the Covenant, Article 4 of the ICESCR clearly
recognizes that it could be limited, when done so by law and "for the
purpose of promoting the general welfare." 1°9
Reconciling the tension between sharing scientific advances and
protecting intellectual property will require balancing not only these
obligations, but also the underlying interests of the parties, including
promoting commerce and protecting public health. In addressing these
competing interests Audrey Chapman explains,
A human rights approach takes what is often an implicit
balance between the rights of inventors and creators and the
interests of the wider society within intellectual property
paradigms and makes it far more explicit and exacting. A human
rights approach is predicated on the centrality of protecting and
nurturing human dignity and the common good. From a human
rights perspective, therefore, the rights of the creator are not
absolute but conditional on contributing to the common good and
welfare of the society. 110
Without trying to create a hierarchy of human rights, it is nonetheless
possible to recognize the fundamental importance of the right to life.
Without it, no realization of other rights is possible. The HIV epidemic
threatens the right to life of millions of people. Rights to private property,
while important, should not take precedence over the right to life. Since
sharing scientific information and medical advances in this case directly
supports the right to life, it ought to be ensured through means that
The State Parties to the present Covenant recognize that, in the enjoyment of those
rights provided by the State in conformity with the present Covenant, the State may
subject such rights only to such limitations as are determined by law only in. so far as
this may be compatible with the nature of these rights and solely for the purpose of
promoting the general welfare in a democratic society.
ICESCR, supra note 82, art. 4.
108. See also UDHR, supra note 81, art. 29, 9I 2; ICCPR, supra note 90, art. 4 ("In time of
public emergency which threatens the life of the nation and the existence of which is officially
proclaimed, the States Parties to the present Covenant may take measures derogating from
their obligations under the present Covenant to the extent strictly required by the exigencies
of the situation, provided that such measures are not inconsistent with their other obligations
under international law and do not involve discrimination solely on the ground of race,
colour, sex, language, religious or social origin....")
109. Limburg Principles on the Implementation of the International Covenant on
Economic, Social and Cultural Rights, Maastricht, June 2-6, 1986, 911 46-56, (providing an
interpretation of Article 4 of the ICESCR on permissible limitations of ESC rights and the
necessary criteria and procedures for such limitation), at http://www.unhchr.ch/tbs/doc.nsf/
(Symbol)/E.C.12.2000.13.En?Opendocument (last visited Apr. 26, 2002) [hereinafter Limburg
Principles].
110. Chapman. supra nnte 61, T 27,
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respect, protect, and fulfill other human rights. If reasonable limitations on
the property rights of authors can bring about greater protection of the
right to life-for instance, by restricting the geographic scope of patent
protection, changing the time of exclusive enjoyment, or permitting uses
under licensing provisions that protect the right to some return on
investment-and these limitations fit within the provisions of existing
international trade and intellectual property regimes, then these limitations
should be considered to be well within what was intended by the drafters
and interpreters of the UDHR and the ICESCR."'
Another approach to reconciliation would understand "authors'
rights" as being intended to protect the creative efforts of individuals or
groups of researchers, but not the monopoly interests of multi-national
corporations or nations. To the degree that protection exceeds individual
needs, it could be limited to ensure other rights.
More generally, human rights considerations in Article 15 of the
ICESCR impose conditions on "authors"' rights protected and by extension
on the international and domestic intellectual property regimes developed
to protect those rights. Intellectual property rights should be limited when
necessary to protect the public health and to the degree necessary to
guarantee the general welfare. As Chapman puts it,
To be consistent with the full provisions of Article 15, the type
and level of protection afforded under any intellectual property
regime must facilitate and promote cultural participation and
scientific progress and do so in a manner that will broadly benefit
members of society both on an individual and collective level.
These considerations go well beyond a simple economic calculus
often governing intellectual property law.
1 2
The basic terms of TRIPS, which grant patent protection to all suitable
processes and products for twenty years with limited exceptions, may
satisfy neither the letter nor the spirit of this human rights mandate if they
deter developing countries from utilizing the measures acceptable under
international law to provide drugs at affordable prices." 3 If the exceptions
to TRIPS are liberally interpreted and respected by both economically
powerful countries and multinational corporations, however, the TRIPS
regime could allow compliance with human rights standards." 4
Recognizing some limitations on the right to intellectual property so as
to respect, protect and fulfill human rights is also wholly consistent with
the Vienna Convention on the Law of Treaties, other trade provisions, and
principles of sustainable development. 115 The United Nations Committee
111. Limburg Principles, supra note 109.
112. Chapman, supra note 61, 29.
113. Id. 62.
114. Weissman, supra note 23, at 1096-1117; see generally, Chapman, supra note 61
(discussing intellectual property as a human right).
115. TRIPS, supra note 35, pmbl.
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on Economic Social and Cultural Rights stated in 1999,
Human rights norms must shape the process of international
economic policy formulation so that the benefits for human
development of the evolving international trading regime will be
shared equitably by all, in particular the most vulnerable sectors
... Trade liberalization must be understood as a means, not an
end. The end which trade liberalization would serve is the
objective of human well being to which international human
rights instruments give legal expression.
116
Utilizing human rights as a framing mechanism offers the advantage of
providing a system of values that can modify economic behavior and
norms, and even the negative aspects of the trend towards globalization. 117
In the words of the U.N.'s High Commissioner for Human Rights: 118
Globalization as an economic process must be subject to the
moral and ethical imperative to which the international human
rights instruments give legal expression .... Human rights provide
a rigorous framework to empower people from around the world
to harness the energies of the global movement and shape a new
globalization that benefits all people. 119
Although the human rights movement has been criticized, rightly or
wrongly, for calling every good a "right," that criticism is inapt in this case.
One need not conceptualize a human right, per se, for access to
pharmaceuticals. Rather, access to pharmaceuticals and other important
advances of science derives from solid obligations under existing, long-
established rights. "Human rights" is important to the access problem
more as a system of law and form of moral persuasion than as a
substantively expanding definitional system. It is one of the few
mechanisms that can be used logically and persuasively to bridge the gap
between the tragic effects and dimension of the HIV/AIDS epidemic and
116. U.N. ESCOR, 21st Sess., 47th mtg. at ' 5, U.N. Doc. E/C.12/1999/9 (1999).
117. Chapman, supra note 61, 1 6.
The establishment of the World Trade Organization in 1994 and the coming into
force of the international [TRIPS Agreement]...have strengthened the global
character of intellectual property regimes....Unless human rights advocates provide
an effective intellectual and organizational counter weight to economic interests, the
intellectual property landscape will be reshaped in the years ahead without
adequate consideration of the impact on human rights.
118. As an official international spokesperson for the United Nations and an advocate of
human rights, the High Commissioner has been recognized for her important work in the
field, especially her contribution to increasing international awareness and recognition of
economic, social, and cultural rights. See, e.g., Press Release, Amnesty International, United
Nations: Mary Robinson's Departure a Loss for Human Rights, Mar. 19, 2002 (Al-index: IOR
40/005/2002).
119. Mary Robinson, Tell Leaders that Human Rights Aren't Optional, INT'L HERALD TRIB.,
Feb. 7, 2002, at 6.
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the unavailability of existing treatments. Guaranteeing access to
pharmaceuticals will also require commitments from the fields of
development and international cooperation and security.
B. Options Under TRIPS
Existing trade provisions permit countries to take certain actions
designed to increase access to pharmaceuticals in order to address. pressing
public health problems. 20  These emergency mechanisms include:
exceptions from patentability; limits on patents where patent holder's
rights are not unreasonably burdened; parallel importing; compulsory
licensing; and generic substitution.121 Countries can also use taxes on
pharmaceuticals, royalties, and price controls that are not discriminatory. 122
The rules allow countries to grant tax breaks and price control variances to
companies that agree to grant non-exclusive licenses for production.
Other innovative strategies are also worth considering. Pharmaceutical
companies could accept the widespread use of tiered pricing (or price
discrimination) that would allow companies to offer drugs for very low
fees in some settings, while maintaining high prices in others (although
companies suspect, perhaps correctly, that this strategy will create pressure
from consumers in more affluent countries to lower all prices).123
Compulsory licensing has received much attention recently for a few
reasons. It offers a potentially powerful tool for countries with pressing
public health needs requiring resort to both new drugs and drugs still
under patent in other countries, particularly high-cost drugs. 24 Major
patent holders have staunchly resisted any efforts by developing countries
to use compulsory licensing for fear of establishing a precedent for
developing countries to avoid honoring patents. 25 However, compulsory
licensing is explicitly allowed under the TRIPS agreement 126 and ought to
be available to developing countries facing crises such as HIV/AIDS or
other deadly epidemics.127 According to one proposed model, governments
seeking to utilize compulsory licensing and comply with TRIPS should: (1)
be simple, avoid overly legalistic provisions or expensive mechanisms (e.g.,
use administrative not judicial mechanisms); (2) include strong
government-use provisions, at least as strong as those adopted by western
countries, such as the U.S., U.K., and Germany; (3) provide a simple system
for setting the level of compensation to patent holders; (4) allow
production for export under specific circumstances; and (5) allow
120. Weissman, supra note 23, at 1098.
121. See supra Subsection III.A for discussion of substance of TRIPS and its exceptions.
122. Weissman, supra note 23, at 1072.
123. European Report, "European Pharmaceutical Industry Defends Third World Actions,"
European Information Services, Mar. 17, 2001, No. 2577.
124. Chapman, supra note 61, 63.
125. Tom Abate, Drug Makers Yield to Pressure; Multinational Firms Offer Tiered Pricing for
Life-Saving Medications, S.F. CHRON., Mar. 25, 2001, at A15.
126. TRIPS, supra note 35, art. 31.
127. Sakboon, supra note 22.
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emergency authorizations to address public health crises.128
The international community could also address some of the
competing burdens faced by developing countries by canceling all or most
of their debt.129 In 1996, the International Monetary Fund and the World
Bank began a program aimed at systematically reducing the debt burden of
many of the world's poorest countries. This project, the Heavily Indebted
Poor Countries (HIPC) Initiative, provides direct assistance for eligible
countries to reduce sharply their foreign debt. An additional initiative,
commenced in 1999, will allow countries to reduce their foreign debt to
150% of the value of their exports or 250% of their annual government
revenues. These mechanisms are expected to relieve about two-thirds of
most countries' debts.130 The World Bank's early evaluation of this
program suggests that it will more than double the funds available in many
countries for social expenditures and that an average of 25% of all debt
relief is going to health care (not including other priority programs
addressing HIV/AIDS).131 While debt relief will not transform poor
countries overnight or make them able to afford high-priced drugs, it could
allow these countries to assume some or all of the costs of imported
generics or to begin building capacity for local manufacture.
Other options involve no challenge to international or national trade
and patent regimes. For example, some suggest that donations and
negotiated discounts are the answer to supplying HIV treatments to the
poorest countries.132 In fact, a number of drug companies have promised
128. James Love, Compulsory Licensing: Models for State Practice in Developing Countries,
Access to Medicine and Compliance zwith the WTO TRIPS Accord (Jan. 21, 2001), available at
http://www.cptech.org/ip/health/cl/recommendedstatepractice.html (last visited Apr. 21,
2002).
129. Marc Borbely, Activists: IMF, World Bank AIDS Recommendations 'Morally Sickening',
UNITED PRESS INT'L, Apr. 18, 2000 (Activists argue that, instead of giving money, the World
Bank, the IMF and the international community ought to cancel the debt of developing
countries in order to allow them to invest in their own infrastructures). On the tenth
anniversary of the Convention of the Rights of the Child, Theo-Ben Gurrirab, President of the
UN General Assembly, noted that the heavy debt of the world's poorest nations makes it
difficult for them to invest in child welfare. He stated that, among countries in Sub-Saharan
Africa, the amount spent on servicing foreign debt each year outweighs their entire
expenditures on health and education, UN Assembly President Calls for "Generous Funds-
Unwavering Commitment" To Realize Culture ofPeace, M2 PRESSWIRE, Nov. 12, 1999.
130. Press Release, The World Bank, World Bank and IMF Support US$3 Billion In Debt
Service Relief For Tanzania Under Enhanced HIPC Initiative, Nov. 27, 2001, (No: 2002/133NB),
available at http://www.worldbank.org/news/pressrelease.nsf (last visited May 7, 2002).
131. As a result of this reduction, countries have increased their spending on social
programs from US $4.4 billion in 1999 to US $6.9 billion in 2002. Estimates are that two-thirds
of total debt relief will be used for education and health care (forty percent for education,
twenty-five percent for health care), while other priority programs include HIV/AIDS
programs. THE WORLD BANK, FINANCIAL IMPACT OF THE HIPC INITIATIVE: FIRST 25 COUNTRY
CASES tables 1, 3, Mar. 2002, available at http://www.worldbank.org/hipc/ Financial_
ImpactMarch0602.pdf.
132. Boehringer Ingelheim Joins Largest-Ever Global Program with United Nations Agencies to
Accelerate Access to HIV/AIDS Care and Treatment in Developing World, UNIV. NEWS SERV., May
11, 2000 (announcing B-I's decision to join the groups offering discounts, and describing other
significant barriers to good treatment and care); James Ciment, U.S. Drug Companies Announce
Vaccine Initiative. 320 BRIT. MFD_ L 73A, Mar 1R 9flfl t(rporq lan lby fur vac. n
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steep discounts across Africa and in other crisis situations. 133 Donations
and discounts, however, do not create reliable sources of supply over the
long term and do not help develop domestic capacity. Both strategies allow
pharmaceutical companies to maintain control of the cost, supply, profits,
and manufacturing capacity of essential medicines.
In 1997 the Joint United Nations Programme on HIV/ AIDS (UNAIDS)
began the HIV Drug Access Initiative (DAI), which is intended to develop
and implement new ways to improve access to HIV drugs and build
treatment capacity in poor countries. Funded by UNAIDS, cosponsors, and
donors, the DAI is a public-private partnership that includes several of the
largest pharmaceutical manufacturers of anti-retrovirals and associated
drugs to treat opportunistic infections. In its first phase, from 1997 through
early 2000, the DAI showed promise in mobilizing a combination of
donors, increasing the capacity of health care workers in the poorest
countries to administer anti-retrovirals, and expanding the program to
other countries. During that time, however, the program brought treatment
to relatively few people with AIDS. 134 Moreover, although DAI was
originally able to secure significant discounts through negotiations with its
pharmaceutical manufacturing partners, by 1999 DAI found it necessary to
utilize the exceptions to patent and trade rules. In 1999 DAI resorted to
negotiating separately with producers of generic versions of several HIV
drugs, beginning discussions with Brazilian manufacturers for generic
versions of anti-retrovirals in March of 2000.135 Unfortunately, HIV
infection rates continue to increase in many developing countries. Some
activists and clinicians, frustrated with moderate approaches to providing
access to pharmaceuticals, desire more aggressive action.136 Radical
manufacturers to donate $150 million worth of "state of the art" vaccines to the developing
world); AIDS Drugs for Poor Nations, Editorial, N.Y. TIMES, Mar. 12, 2001, at A14 (reporting
that Merck was lowering the price of two important HIV drugs to one tenth of what they sold
for in western countries).
133. Maggie Farley, Six Companies Agree to Discounts as U.N. Prepares Massive Campaign
Against the Epidemic, L.A. TIMES, Apr. 6, 2001, at A1-14 (Kofi Annan successfully negotiates
discounts from six companies at the same time the U.N. campaign against AIDS announced);
Abate, supra note 123 (noting that drug company offers of discounts were being made as an
attempt to head off international action that could lead to the undermining of patents); Gavin
Yamey, Drug Companies Cut HIV Drug Prices in the Developing World, 320 BRIT. MED. J. 1357,
May 20, 2000 (discussing the decision of five multinational firms to cut the price of HIV drugs
in the developing world).
134. From 1997 to 1999, pilot programs were set up in Uganda, C6te d'Ivoire, Chile and
Vietnam. In addition to setting up national advisory boards and training doctors and other
health care workers to use anti-retrovirals and to treat opportunistic infections, the DAI
managed to get modest numbers of people with HIV/AIDS on anti-retroviral therapy (ARV).
The initial meeting evaluation reported that in Uganda, out of an estimated one million
people with HIV/AIDS, 900 were on ARV; in C6te d'lvoire, out of an estimated 800,000
infected, 650 were on ARV; in Chile, out of 16,000 infected, 2500 were on ARV; and in
Vietnam, out of an estimated 88,000 infected, seventy were on ARV. REPORT ON UNAIDS
INITIATIVE, supra note 5, at 6-7.
135. Id. at 4 (reporting that, after initial negotiations with companies brought no more
discounts, DAI began working with generic manufacturers).
136. Donald Berwick, "We All Have AIDS": Case For Reducing the Cost of HIV Drugs to Zero,
324 BRIT. MED. J. 214, 214-16, Jan. 26, 2002; Achmet, supra note 68, at 214-18.
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solutions include changing or abolishing TRIPS, removing medicine and
health-related products entirely from the current system of intellectual
property protections, and returning to an earlier type of intellectual
property system that extended patent protection only to processes and not
to products. This last approach has allowed countries such as India to
develop a thriving domestic pharmaceutical industry. 137 India has
benefited from its own internal manufacturing of cheap generics and
produces the least expensive anti-retrovirals in the world.138 Latin
American countries in particular have adopted other legal means to
improve access to pharmaceuticals.
VI. CASE STUDY: BRAZIL AND ACCESS TO ANTI-RETROVIRAL MEDICATIONS
A. Medications
In several countries in Latin America, including Brazil, Costa Rica,
Argentina, Colombia, Chile and Venezuela, advocates have used legal
measures including legislation and the courts to establish a "right to
treatment" with HIV medications.139 These efforts were made possible by
the widespread incorporation into Latin American law of the rights to
health, health care, and the benefits from scientific advances. 140 Brazil's
government has made treatment of all those infected with HIV its goal and
has taken important steps through its legal, public health, pharmaceutical
sectors to make this a reality. How Brazil addressed this issue, its relative
successes and challenges it continues to face can provide instruction for
other countries.
B. Brazil's HIV Epidemic
In the early 1990s, Brazil faced a rapidly increasing epidemic of
HIV/AIDS. In 1994, the World Bank projected that Brazil would have 1.2
million people living with HIV by the year 2000.141 The Brazilian
government, its industries, and its people mobilized to defy that grim
prediction. By adopting a policy that guaranteed all persons with HIV the
right to free anti-retroviral medication, focusing its prevention efforts, and
reinforcing its public health infrastructure to facilitate both effective
prevention and treatment efforts, Brazil reached the year 2000 with only
137. Judy Rein, International Governance Through Trade Agreements: Patent Protection for
Essential Medicines, 21 Nw. J. INT'L L. & Bus. 379, 386 (2001).
138. Ellen 't Hoen & Suerie Moon, Pills and Pocketbooks: Equity Pricing of Essential Medicines
in Developing Countries (July 11, 2001), available at http://www.accessmed-
msf.org/upload/ReportsandPublications/20920021811218/4-5.pdf.
139. Enrique Gonzalez Mac Dowell, Juridical Action for the Protection of Collective Rights
and Its Legal Impact: a Study Case 2 (Aug. 2000) (on file with author); see also infra note 173
(noting Brazilian legislative strategies).
140. MacDowell, supra note 139.
141. Piot, supra note 19.
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540,000 people infected with HIV.1 42 AIDS deaths during this period
decreased by sixty percent.143 Part of this success was due to greatly
increased access to anti-retroviral therapy for persons living with HIV. In
1997 approximately 25,000 persons in Brazil received combination therapy;
by 2002 at least 100,000 were on therapy."4 Brazil's Minister of Health
identifies three principles responsible for the country's success in
delivering free universal HIV care: (1) committed leadership at the top; (2)
involvement of community and civil society groups in efforts to reach poor
and deliver treatment; and (3) affordable medicines. 145
Increased access was attributable largely to government commitment,
the reduced costs of pharmaceuticals made possible by domestic
manufacture of generic drugs, and negotiated price discounts for other
drugs. 146 The actual costs of HIV therapy in Brazil have fallen from an
estimated annual cost of $7,858 per person in 1997 to $4,137 per person in
2001.147 In the United States, the same regimens cost between $10,000 and
$15,000 annually. Additionally, although the Brazilian government spent
between $300 million and $320 million per year in the late 1990s to provide
HIV care, it saved an estimated $420 million on hospital costs over the
same period, because fewer patients with HIV were getting sick and
dying.
148
C. Brazil's Intellectual Property and Patent Laws
Like many developing countries, Brazil did not recognize or enforce
patents on pharmaceuticals before 1994. After joining the WTO, Brazil
began the process of adopting legislation that would fulfill the TRIPS
requirements. In 1996, it enacted the Industrial Property Law, 149 which
provided patent protection for drugs (and other industrial products)
developed after that time as long as the manufacturer conducts some part
of the drug's manufacture in Brazil.' 5 This "local working" requirement, in
addition to the TRIPS clause that exempts from patent protection drugs in
existence prior to 1994, has enabled the Brazilian government to license




145. Trudy Rubin, Africa Must Learn from Brazil's AIDS Fight, BALT. SUN, July 5, 2001, at
11A (Brazilian Health Minister Jose Serra's description of success of program).
146. Id.
147. Interests that Kill: US Pressures Brazil To Abandon Successful AIDS Program, ACTION
ALERT (Int'l Gay & Lesbian Human Rights Comm., San Francisco, CA), Feb. 6, 2001 at
http://www.iglhrc.org/world/ southamerica/Brazil2001Jan.html (last visited Apr. 4, 2002).
148. Miriam Jordan, Merck Vows AIDS Help for Brazilians, WALL ST. J., Mar. 29, 2001, at A10.
149. Lei No. 9.279, de 14 de maio de 1996, D.O.U. de 15.05.1996, at http://
www.cptech.org/ip/health/cl/ brazill.html (last visited Apr. 28, 2002) [hereinafter Law No.
9.2791.
150. Id. art. 68 (requiring patent holders to manufacture their patented products in Brazil
or be subject to compulsory licensing).
151. Naomi A. Bass, Note, Implications of the TRIPS Agreement for Developing Countries
Pharmaceutical Patent Laws in Brazil and South Africa in the 21st Century, 34 GEO. WASH. INV'L L.
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In 1999, the. President of Brazil issued a decree establishing rules for
compulsory licensing using another provision of the 1996 patent law that
permits compulsory licensing in cases of national emergency, including
situations in which there is an impending public health crisis252 This
would allow licensing of post-1994 drugs. Thus far, Brazil has not issued
compulsory licenses under this provision, but it has used the threat of
licensing to encourage companies to negotiate price discounts.1 53
D. Brazil's Economy and Health Statistics
The World Bank classifies Brazil as an upper-middle-income
country. 154 Its per capita GDP of $6,500155 lies well above levels in many of
the world's poorest nations,156 but far below the $36,000 mark of the United
States. 57 Life expectancy in 1999 was sixty-seven years and infant mortality
was thirty-two per 1000 live births. Eighty-seven percent of its population
has access to safe water and 77% to improved sanitation. 58 These average
figures mask substantial inequalities in income and health status. The "Gini
index," a well-known indicator of national income inequality, rates Brazil
as 148th out of 150 countries, showing that income disparities in Brazil are
among the starkest in the world. 5 9 Extreme disparities in income are
associated with disparities in health status, meaning that the poorest
Brazilians remain highly vulnerable to ill health.160 Despite Brazil's middle-
REV. 191, 207 (2002).
152. Presidential Decree No. 3.201 of Oct. 6, 1999 (establishing rules concerning the
granting, ex officio, of compulsory licenses in cases of national emergency and public interest
provided for in article 71 of Law No. 9.279), at http://www.cptech.org/ip/health/c/brazil/
PresDecree.html (last visited Apr. 28, 2002).
153. Bass, supra note 151, at 209; Sakboon, supra note 22.
154. WORLD BANK GROUP. DATA AND STATISTICS: COUNTRY CLASSIFICATION, at
http://www.worldbank. org/data/countryclass/classgroups.htm (last visited May 9, 2002).
Brazil is classified as upper-middle-income. This group includes thirty-eight countries with
gross national income (GNI) per capita between $2,996 and $9,265 per year. For comparison,
low income countries have GNIs per capita of less than $756 per year (there are sixty-three
countries in this bracket, including at least thirty-five in Africa). Id.
155. CIA, THE WORLD FACTBOOK (2001) (giving information on geography, economy,
government and other aspects for each country), at http://www.cia.gov/cia/publications/
factbook/ (last visited Apr. 29, 2002). Other middle-income countries with significant
HIV/AIDS epidemics include South Africa, per capita GDP of $8,500; Botswana, per capita
GDP of $6,600; Namibia, per capita GDP of $4,300. Lower-middle income countries include
India, per capita GDP of $2,200 and Zimbabwe, per capita GDP of $2,500.
156. Id. Angola has a GDP per capita of $1,000; the Congo has a GDP per capita of $600;
Guinea-Bissau has a GDP per capita of $850 and Malawi has a GDP per capita of $900.
157. Id. (describing same sectors for the United States).
158. Brazil: -Social Services, World of Information Country Report, QUEST ECONOMICS
DATABASE, JANET MATrHEWS INFO. SERVS., Mar. 18, 2002, at 16. Worldwide, eighty-eight
percent of people have safe water, while only sixty percent have adequate sanitation. WHO,
Water and Sanitation, at http://www.who.int/m/topics/water-sanitation/en/index.html (last
visited Feb. 11 2002).
159. Rodolfo Espinoza, Too Rich, Too Poor, BRAZIL, May-June 2000, at
http://www.brazzil.com/cvrmayoo. htm (last visited Apr. 4, 2002).
160. Hooman Momen, Emerging Infectious Diseases-Brazil, 4 EMERGING INFECTIOUS
DISEASES, Jan.-Mar. 1998, (describing major emerging infectious diseases in Brazil including
malaria, American Trypanosimiasis Leis aniasis, dengue fever, es, AIDS and other
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income status, Brazilians experience relatively high rates of malaria,
measles, cholera, hepatitis and a range of other parasitic and viral
infections, including HIV/AIDS.
161
Brazil's strategy -to guarantee access to pharmaceuticals, strengthen
its public health infrastructure, and use a combination of generic
manufacture and direct and indirect negotiation with drug companies to
drive down costs-may have other health benefits. These benefits may
include strengthening the network of public health and primary care
providers and, more generally, educating the population about health
issues. Critics of efforts to provide universal access to HIV therapies,
however, argue that providing treatment will have opportunity costs. They
argue that funds needed to provide primary care or fight other diseases
will be diverted to AIDS, to the detriment of overall health. Brazil's
experience suggests otherwise. Brazil hopes to save on future medical care
costs through current spending on AIDS therapies. It is projected that
Brazil's investment of $444 million on AIDS drugs in 2000 will allow it to
realize substantial savings through prevented future hospitalizations. 6 2 In
2001, Brazil passed on the $35 million savings achieved through this
strategy to fund other public health initiatives directed at low-income
families.163 Although opportunity costs should factor into designing
optimal public health interventions, 64 HIV treatment is a worthy priority
that must not be neglected.
E. Brazil as a Model
Director of UNAIDS Peter Piot,165 the UN,166 the Inter-American
Bank 67 and numerous activists, including South African labor unions,168
have hailed Brazil's achievements in providing HIV/AIDS therapy as a
resounding success and potential model for other developing countries.
Brazil's achievements in these areas have drawn substantial criticism,
however, from TRIPS supporters, 169 the pharmaceutical industry, and
viral diseases such as hepatitis A and D, cholera and various fungal infections), at
http://www.cdc.gov/ncidod/EID/vol4nol/momen.htm.
161. Id.
162. "The only study of the program's benefits so far shows that the decline in
hospitalizations from opportunistic infections from 1997 to 1999 saved the Health Ministry
$422 million." Tina Rosenberg, Look at Brazil, N.Y. TIMES, Jan. 28, 2001, § 6 (Magazine) at 26.
163. Discounts Here to Stay, Kevin Gopal, 21 Pharmaceutical Executive 24 (No. 10, Oct. 1,
2001) ("the ministry threatened to invoke a compulsory license to manufacture Viracept
(nelfinavir), forcing Roche to cut its price by 40 percent").
164. GOsTIN & LAZZARINI, supra note 79, at 61-63.
165. Piot, supra note 19.
166. Peter Capella & James Meikle, U.N. Backs Use of Cheap Generic Anti-AIDS Drugs, THE
GUARDIAN (London), Feb. 21, 2001, at 3.
167. Elena Moreno, Latin America-HIV/AIDS IDB Urges Countries to Adopt Brazil's
HIVIAIDS Prevention Model. EFE NEWS SERV., Mar. 8, 2002.
168. Congress of South African Trade Unions, South Africa; Defeating HIV: Now is the
Time!, AFR. NEWS, Feb. 14, 2002.
169. TREBILCOCK & HOWSE, supra note 28, at 310-12 (noting that the recording industry and
various manufacturers of frequently copied goods-such as "Rolex" watches-also strongly
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powerful countries such as the United States. The U.S. brought a complaint
to the WTO seeking review of Brazil's Industrial Property Law for possible
violations of TRIPS. 70 The U.S. dropped its suit after Brazil agreed not to
export its generic drugs.17 1 News that Medecins San Frontieres (Doctors
Without Borders) entered into an agreement with Brazilian companies to
purchase combination therapy in Brazil for trials in South Africa 72
suggests that the potential for controversy still exists and that Brazil might
again find itself the subject of U.S. or pharmaceutical industry complaints.
F. Challenges Still Facing Brazil
Brazil's achievements may also be eroded by other developments,
chiefly the passage of time. Brazil can argue legitimately that it should be
able to manufacture generic versions of the anti-AIDS drugs that existed
supported the mandate for all countries to adopt stronger patent provisions under TRIPS).
170. Sarah Boseley, Brazil Faces Sanctions Over Cheap AIDS Treatment, Editorial, SYDNEY
MORNING HERALD, Apr. 21, 2001, at 18; No Patent on Compassion, ST. Louis POST-DISPATCH,
Feb. 20, 2001, at B14 (In January 2001, the U.S. asked the WTO to form a trade court to hear
patent dispute with Brazil). For the U.S. Trade Representative's perspective on the conflict
with Brazil over threats to use compulsory licensing, see SPECIAL REPORT OF THE U.S. TRADE
REPRESENTATIVE 10, Apr. 30, 2001, available at http//:www.cptech.org/ip/health/c/brazil (last
visited Apr. 28, 2002.)
171. The United States has a history of objecting to Brazil's intellectual property regimes.
In 1987 the U.S. imposed a 100 percent tariff on selected Brazilian imports to the U.S. to signal
its disapproval of the existing Brazilian law. Michael Manoochehri, Unethical Patent Law: How
the United States and the WTO Impact the Health of Brazilian Citizens, FREE INFORMATION
PROPERTY EXCHANGE, Apr. 26, 2001, available at http://www. freeipx.org/display.php3?id=46.
The U.S. calculated its penalties to match the estimated $39 million it claims were lost to
American pharmaceutical companies. Weissman, supra note 23, at 1078-79. Brazil's enactment
of the 1996 law represented an attempt to avoid another costly round of sanctions. However,
the willingness of the Brazilian government to encourage local manufacture of generic (un-
patented) drugs in Brazil, and to threaten to issue compulsory licenses for newer drugs has
drawn the continued ire of both the U.S. government and pharmaceutical companies. The U.S
brought one complaint to the WTO and, although it dropped the suit, it may initiate
complaints in the future. In a joint communication, the U.S. and Brazil agreed to a resolution
of the dispute about the compatibility of Article 68 of Brazil's Industrial Property Law (Law
No. 9.279, art. 96) with the TRIPS Agreement as follows:
Without prejudice of the U.S. and Brazil's different interpretations of the consistency
of Article 68 with the TRIPS Agreement, the U.S. Government will withdraw the
WTO panel against Brazil concerning the issue, and the Brazilian Government will
agree, in the event it deems necessary to apply Article 68 to grant compulsory
license on patents held by U.S. companies, to hold prior talks on the matter with the
U.S. These talks would be held within the scope of the U.S.-Brazil Consultative
Mechanism, in a special session scheduled to discuss the subject.
Joint Communication Brazil-United States, June 25, 2001, available at
http://www.cptech.org/ip/health/ c/brazil/statement06252001.html; Press Release, Office of the
U.S. Trade Representative, United States and Brazil Agree to Use Newly Created Consultative
Mechanism To Promote Cooperation on HIV/AIDS and Address WTO Patent Dispute, June
25, 2001, available at http://www.ustr.gov; Laurie Garrett, U.N. Session Faces Hurdle; Muslim
Nations Balk at Language on Gays, NEWSDAY, June 26, 2001, at A07 (noting that the U.S. dropped
its claim against Brazil in the WTO trade court when Brazil agreed not to export generic drugs
manufactured in Brazil).
172. Medecins Sans Frontieres Imports Generic Drug in Challenge to Patent Laws, VIRUS
WEEKLY, 13 (Feb. 19, 2002) (announcing that MSF will import combination therapy
manufactured in Brazil to Souhh Africa for use in clinical trials).
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before 1994, because TRIPS applies only to drugs patented and placed on
the market after that date. The evolving nature of anti-HIV therapies means
that new drugs are being developed all the time and are necessary to treat
a rapidly mutating virus. Pre-1994 drugs will soon be obsolete for many
patients. TRIPS does not extend such lenient terms to post-1994 drugs, the
drugs that will provide the most effective treatment.
Brazil will have to face several difficult alternatives. The government
could pay market prices for new drugs (impossible at current prices), seek
compulsory licensing of drugs patented since 1994,173 or continue to try to
negotiate directly with pharmaceutical companies for steep discounts on
future drugs. So far, the government has successfully used the threat of
issuing compulsory licenses to persuade drug companies to negotiate price
discounts on new H1V drugs.174
Other challenges concern the long-term impact of TRIPS and the
Industrial Products Law on investment in Brazil's domestic pharmaceutical
industry. Domestic manufacture of generic drugs under threat of
compulsory licensing could deter developers of new pharmaceuticals from
operating in Brazil if they felt that their patents would not be enforced by
the government. On the other hand, a robust manufacturing sector-even
one based on imitation of existing drugs-could benefit the economy and
the pharmaceutical industry. First, building capacity to manufacture
generic drugs could help meet more general public health needs by
preventing or curing other illnesses with drugs that have been off-patent
for years. Second, providing universal access to HTV medications for
persons with HIV will reduce the numbers of productive workers lost to
HIV/AIDS over future years, provide an ongoing market for domestically
produced generic HIV drugs, and reduce national costs for hospitalization
and related care. Savings in these areas could be devoted to other public
health objectives or to funding government-sponsored research and
development of new drugs.
G. Future of Brazil's Program
As in other countries, the future of Brazil's efforts to offer HIV
therapies depends on many factors. One key determinant will be the
willingness of developed countries to respect the flexibility provided in the
TRIPS agreement for developing countries to respond to local conditions,
including public health needs, economic crises, and claims of indigenous
groups.175 If developed countries do not respect these aspects of TRIPS, it is
unlikely that developing countries will be able to meet the dual obligations
facing them: to provide intellectual property protection within the
173. Compulsory licensing is permitted under art. 31 of TRIPS. Brazil has potential routes
available under its national law to utilize this exception. See Law No. 9.279, supra note 149, art.
68 (permitting generic manufacture of drugs that are not locally produced), and art. 71
(permitting compulsory licensing to address a national health emergency).
174. Bass, supra note 151, at 209.
175. Id. At 220-22.
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international framework while promoting access to pharmaceuticals
desperately needed to fight AIDS, malaria, TB, and other pandemics of
deadly disease.
H. Brazil's Success May Be Key to Options for Poorer Countries
The future of Brazil's efforts, and those of other middle-income
countries, may be interconnected with the potential options for poorer
countries. While Brazil, South Africa, Thailand, India and other middle-
income countries with industrial bases have the potential to manufacture
drugs domestically, other countries lack a functional industrial base,
transportation, banking institutions, or other assets necessary to build
domestic industry. Such countries are among the poorest in the world-
including many in Africa, the Caribbean and Asia -as well as those whose
infrastructure or economies have been destroyed by war or civil conflict.
For all these reasons the poorest countries may have few options for acting
alone under TRIPS. One option for these countries -parallel importing-
would be facilitated by development of regional capacity to manufacture
generic drugs in countries like Brazil or India. Generic pharmaceuticals in
excess of the domestic needs could be exported to the poorest countries,
helping to meet their needs while also benefiting the middle-income
producers of generics. For example, the Associacion Agua Buena, a human
rights organization based in Costa Rica, has gone public with an offer to
buy combination therapy manufactured generically in Brazil for patients in
other countries in the region.176 The pharmaceutical industry fears this type
of export of generically manufactured drugs as the beginning of
"arbitrage" -the development of a parallel international market in generics
that could decrease companies' profits from sales of patented drugs. 177
Both pharmaceutical manufacturers and the U.S. may oppose this request.
The benefits to generic manufacturers such as Brazil depend as well on
both the level of demand-which can be increased if a legal right to
treatment is established-and the ability of poorer countries to pay for
imports. Organizations like Associacion Agua Buena have sought to force
government agencies to provide HIV treatment by bringing cases on behalf
of individuals in hopes of establishing legal precedents that articulate a
right to HIV treatment, including combination therapy.' 78 Such legal
obligations might put more countries on the market for low-cost, generic
pharmaceuticals from Brazil or other countries. In 1997, several persons
176. In an open letter to the Health Minister, the Association offered to pay the full annual
costs of the treatment and shipping for a patient named Ibel Martinez in Honduras. Letter
from Richard Stem, Executive Director, Association Agua Buena, to Dr. Paulo Teixeira, Brazil
Ministry of Health (Apr. 7, 2002) (on file with author).
177. European Report, supra note 123.
178. Associacion Agua Buena petitioned the Interamerican Human Rights Commission on
behalf of an individual living with HIV/AIDS in El Salvador. Enrique Gonzalez Mac Dowell,
Juridical Action for the Protection of Collective Rights and Its Legal Impact: A Study Case
(Sept. 29-Oct. 1, 2001) (paper presented at the American Society of Law, Medicine, and Ethics
Annual Meeting Honoring Jonathan M. Mann.)
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with HIV/ AIDS successfully petitioned the Costa Rican Supreme Court to
order the national social security system to provide them triple anti-
retroviral therapy.179 The government began to comply with the order and
provide patients with triple therapy in late 1997.180 The groundwork for
this decision was laid, in part, by Costa Rica's adoption of a law
prohibiting discrimination against persons with HIV/AIDS.181
I. Beyond Brazil: Continuing Challenges Achieving Universal Access
Even if parallel importing were allowed, however, and prices dropped
to $1 a day or less,182 many countries, including those hardest hit by
HIV/AIDS in Africa, might not be able to afford treatment for all those
who need it. In some countries treatment costs are greater than the yearly
income of most residents and far exceed the annual per capita health
budget. Moreover, many countries simply lack an adequate public health
infrastructure, skilled personnel, and laboratories to deliver such care.
The situation in lower- and lowest-income countries illustrates a
separate, but related, failing of the current international system. Although
international agreements, including the WTO and the international human
rights instruments, obligate richer nations to assist poorer nations in
realizing the benefits of the treaties, 183 national commitments often fall far
179. Press Release, Association Triangulo Rosa, Costa Rican Supreme Court Rules
Government Must Provide New AIDS Meds (Sept. 30, 1997) (on file with author). In two court
rulings issued on Sept. 23 and 25, 1997, the Supreme Court of Costa Rica ordered the national
social security agency, Caja Costarricense de Seguro Social or CCSS, to pay for triple
combination therapy with HIV anti-retrovirals for William Garcia three other plaintiffs living
with AIDS. Local advocates expected the decisions to open the door for many other Costa
Rican's with HIV/AIDS to apply directly to CCSS to receive treatment.
180. Richard Stem, The Psychologist as Advocate: Access to Medication for People with AIDS in
Costa Rica, at IT 39-41 (2000) (unpublished article e-mailed from Stem, on file with author)
(describing history of advocacy since 1996 in Costa Rica, culminating with Supreme Court
cases, and describing early implementation of the court order). Stern reports, "By agreement
with the Judges, People with AIDS will receive the medications when their T-4 Cell Counts
are below 350 or when they have become ill with 'opportunistic infections."' Id. 1 41. As of
March 2000, 440 Costa Ricans were reportedly receiving combination therapy pursuant to this
order. Mortality from AIDS reportedly dropped from 102 in 1997 to forty-four in 1998. Id.
42.
181. Letter from Richard Stern to Jorge Taiana, Secretary, Interamerican Human Rights
Commission (Sept. 25, 1999) (on file with author) (petitioning for an immediate order
directing the government of El Salvador to provide HIV/AIDS medicines for Odir Miranda, a
citizen of El Salvador living with AIDS, includes mention of Costa Rican law).
182. Kumar Sanjay, Indian Company Offers Low Cost AIDS drugs, 357 THE LANcET 616 (Feb.
24, 2001) (Cipla offers to sell combination therapy for $1200 per year wholesale; $600 per year
to governments; $350 per year to Medecins Sans Frontieres).
183. Marrakesh Agreement Establishing the World Trade Organization, in Final Act
Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations, Apr. 15,
1994, 33 I.L.M. 1125 (1994) ("Recognizing further that there is need for positive efforts
designed to ensure that developing countries, and especially the least developed among them,
secure a share in the growth in international trade commensurate with the needs of their
economic development."); ICESCR, supra note 82, art. 2 ("Each State Party to the present
Covenant undertakes to take steps, individually and through international assistance and co-
33
Lazzarini: Making Access to Pharmaceuticals a Reality: Legal Options Under TRIPS and the Case of Brazil
Published by Yale Law School Legal Scholarship Repository, 2003
YALE HUMAN RIGHTS & DEVELOPMENT L.J.
short of what is needed. Take for example the new Global Fund to Fight
AIDS, Tuberculosis, and Malaria. UNAIDS has estimated that successfully
combating the AIDS epidemic will require $10 billion/year. To date, the
Fund has only received pledges of $2.1 billion and actual funds of $1.2
billion. The U.S. government has contributed about $500 million.184
Compare this to the U.S. defense budget (FY99, before the "war on
terrorism" began) of $276.7 billion, and our national spending priorities
become painfully apparent. While international commitment exists on
paper to support poor countries' fight against AIDS, this commitment is
dwarfed by the measures taken to prepare for war and provide for national
defense. This is so, even though the U.S. State Department, Kofi Annan,
and Peter Piot note that AIDS represents the one of greatest threats to
security in the world, by harming economies, destabilizing societies, and
leaving large numbers of children without parents, education, homes, or
socialization.
185
Creating real opportunities to increase access to drugs will require
meeting a number of challenges. First, a key problem remains concerning
how to guarantee government commitment and resources to provide
access to pharmaceuticals, especially during difficult economic times.
Second, although the current intellectual property system may be
interpreted or modified, if necessary, to permit access to drugs at
affordable prices, the international community must still fulfill the long-
term need for sustainable domestic development and public health
capacity. Such development will in turn make each country more
independent and more able to support its own comprehensive public
health infrastructure. A robust public health infrastructure will reduce
morbidity and mortality from all causes and perhaps prevent the next
pandemic. Using a human rights framework to establish a "right to access
to pharmaceuticals" and modifying international law to respect and fulfill
that right may be a necessary first step, but it will be insufficient by itself to
create meaningful, long-term capacity and commitment to address public
health needs and health emergencies. 8 6
operation, especially economic and technical, to the maximum of its available resources, with
a view to achieving progressively the full realization of the rights recognized in the present
Covenant by all appropriate means, including particularly the adoption of legislative
measures."); art. 15 ("The steps to be taken by the States Parties to the present Covenant to
achieve the full realization of this right shall include those necessary for the conservation, the
development and the diffusion of science and culture. 3. The States Parties to the present
Covenant undertake to respect the freedom indispensable for scientific research and creative
activity. 4. The States Parties to the present Covenant recognize the benefits to be derived
from the encouragement and development of international contacts and co-operation in the
scientific and cultural fields.")
184. The Global Fund to Fight AIDS, Tuberculosis & Malaria, Pledges, available at
http://www.globalfundatm.org/files/Financial-contributions_011002.htm (last visited Nov. 21,
2002).
185. Piot, supra note 19.
186. Robinson, supra note 119, at 6 (In a globalized civil society, corporations must share
responsibility for humanizing globalization, including respecting human rights and
integratine them into corporate docision-making standards.)
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J. Other National Examples
Recent developments in South Africa illustrate both the potential for
legal solutions supported by strong international pressure18 7 and the
inability of legal solutions (so far) to overcome a lack of government
commitment to the specific goal of providing HIV/AIDS therapy.
Although South African law permits domestic manufacture of generic
drugs and Indian companies have offered generic combination therapy to
the government of South Africa, NGOs, and individuals at relatively low
prices,188 the government has begun no widespread program to promote
HIV treatment. Nor has the government or local pharmaceutical firms
initiated generic production.
189
India faces another dilemma entirely, with a domestic industry capable
of producing medicine at affordable prices but a web of local laws keeping
domestic prices relatively high, an overall lack of resources in the health
budget to cover anti-HIV drugs - even at affordable prices - and the need
to conform its laws to TRIPS in the near future. 190 One proposal to reconcile
TRIPS demands with the needs of Indian citizens is to reduce corporate
taxes on research and development for pharmaceuticals. 191 The hope is that
this would allow India's pharmaceutical companies to compete in the
international pharmaceutical market with its own patented drugs.
192
VII. CONCLUSION
Viewed in the context of international law and ethics, it is possible to
understand access to affordable pharmaceuticals for deadly diseases as no
less a human rights issue than the protection of "authors"' rights to the
benefits of their creations. Human rights instruments provide a potential
structure for balancing these seemingly conflicting interests that is
supported by language in trade agreements, official statements of trade
bodies, rules of interpretation of treaties, and other international norms.
Human rights provisions were intended, among other goals, to influence
the application and implementation of trade provisions. These provisions
should be interpreted to complement and promote fulfillment of
substantive human rights norms. Intellectual property protections adopted
to protect the fundamental rights of authors and other creators are not
187. Editorial, South Africa's AIDS Victory, N.Y. TIMES, Apr. 20, 2001, at A18.
188. Sanjay Kumar, Indian Company Offers Low Cost AIDS Drugs, THE LANCET, Feb. 24, 2001
(describing Cipla's plans to offer combination therapy at $350 per year to Medecins Sans
Frontieres, $600 per year to governments, and $1200 per year to individuals and noting that
the cost of similar therapy in Western markets is $10,000 to $15,000 per year).
189. See South Africa's AIDS Victory, supra note 178; Jon Jeter, Trial Opens in South Africa
AIDS Drug Suit: Firms Seek to Block Law Allowing Generic Substitutes for Patented Medicines,
WASH. POST, Mar. 6, 2001, at Al (describing efforts by the pharmaceutical industry to block a
1997 law allowing the South African government to override patents on AIDS medicines).
190. Suresh Koshy, The Effect of TRIPS on Indian Patent Law: A Pharmaceutical Industry
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absolute. Property rights must be limited to the degree necessary to protect
the public health and general welfare in democratic societies. Numerous
mechanisms already exist that can modify intellectual property rights
without abrogating a right to property, removing incentives to innovation,
or threatening research and development of new drugs. These mechanisms
include: tiered pricing, promoting manufacture of generics that are off
patent, seeking compulsory licensing for crucial drugs, parallel importing
and developing an international framework to prevent resale of
inexpensive drugs in Western markets. These devices should be applied
first, but other innovative strategies should also be considered. Such
strategies might include higher levels of debt relief for the poorest
countries, taxing pharmaceutical company profits to support treatment or
R&D in developing countries, shortening the term of patent protection or
eliminating patents entirely for some countries.
International human rights provide a legal structure for advocacy for
access to treatment and a range of advocacy strategies, both within the
legal system and based on moral persuasion. Advocates and activists have
begun to use these tools to establish a "right to treatment" in various
countries and to persuade governments to make access to pharmaceuticals
a priority. Multinationals and developed countries have not evidenced a
willingness to respect the flexibility remaining in the new intellectual
property system. This may significantly undermine the confidence of
developing countries in the value of this system. Governmental and
business endorsement of a more flexible approach may be dependent on
the recognition by both developed and developing countries that AIDS
represents an actual emergency.
On a larger scale, challenges include how to promote sustained
development of the poorest nations and to secure the international resource
commitment that will be necessary if medicines are to be made widely
available at affordable prices. The international community has thus far not
stepped up to share resources, provide sustained commitment, or. help
build infrastructure. Advocacy on these issues is at least as important as
legal battles to establish a "right to treatment."
After two decades of focusing on tracking and trying to prevent spread
of HIV/AIDS, the world community now has a real opportunity to reduce
the tragic gulf between treatments available to those in the developed and
developing worlds. In the process we could help obtain life-extending
treatments for millions of those infected around the world. Increasing
treatment should not decrease efforts to prevent new infections, nor should
any of those at risk feel complacent about the burden of HIV infection.
However, if we fail to decrease the disparity between those worlds now we
will miss a real opportunity to bolster both public health and human rights.
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